var title_f12_16_12544="Varicocele PI";
var content_f12_16_12544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F70115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F70115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Varicocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A varicocele is a collection of swollen veins inside the scrotum. These swollen veins make the scrotum look like a bag of worms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12544=[""].join("\n");
var outline_f12_16_12544=null;
var title_f12_16_12545="Ovarian cancer color doppler";
var content_f12_16_12545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ovarian cancer color doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal ultrasound image of an ovarian cancer of the left ovary. The ovarian mass is 4.7 cm and primarily solid as indicated by the long arrow. Color Doppler imaging demonstrates blood flow within the solid portion of the ovarian mass (short arrow). Almost no normal ovary is visible in the image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thomas D Shipp, MD. Copyright &copy; Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12545=[""].join("\n");
var outline_f12_16_12545=null;
var title_f12_16_12546="Y exercise for scapular stabilizers";
var content_f12_16_12546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    \"Y\" exercise for scapular stabilizers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 202px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    \"Y\" exercises are performed with the elbows extended and the thumbs pointing up. Flex your shoulders in a plane at approximately a 45 degree angle from&nbsp;your body until the arm or arms are in line with the body. Hold the position for one second, and then slowly return the arms to the starting position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12546=[""].join("\n");
var outline_f12_16_12546=null;
var title_f12_16_12547="Multiple myeloma symptoms, diagnosis, and staging";
var content_f12_16_12547=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?12/16/12547/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/16/12547/contributors\" id=\"au133\">",
"       S Vincent Rajkumar, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?12/16/12547/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/16/12547/contributors\" id=\"se3048\">",
"       Robert A Kyle, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?12/16/12547/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/16/12547/contributors\" id=\"de1889\">",
"       Rebecca F Connor, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?12/16/12547?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      MULTIPLE MYELOMA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow. Normally, plasma cells produce antibodies and play a key role in immune function. However, uncontrolled growth of these cells leads to bone pain and fractures, anemia, infections, and other complications.",
"    </p>",
"    <p>",
"     In the United States, about four people per 100,000 are diagnosed with MM each year. This condition is slightly more common among men than women, and almost twice as common among blacks as among whites. The average age at diagnosis is 65 to 70 years.",
"    </p>",
"    <p>",
"     The current treatment options for MM include watchful waiting (for asymptomatic or smoldering multiple myeloma), chemotherapy, treatment with immune modulating medications, and stem cell transplantation. Multiple myeloma is seldom cured, although treatment can relieve symptoms, induce remission, and prolong life.",
"    </p>",
"    <p>",
"     The cause of MM is unknown. Exposure to radiation, organic chemicals (such as benzene), herbicides, and insecticides may play a role. Genetic factors and viral infection may also influence the risk of developing multiple myeloma.",
"    </p>",
"    <p>",
"     This topic review discusses the signs and symptoms, diagnostic tests, and staging system used for people with multiple myeloma. The treatment of multiple myeloma is discussed in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"      \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      MULTIPLE MYELOMA FEATURES",
"     </span>",
"    </p>",
"    <p>",
"     Multiple myeloma can produce a wide variety of symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Bone symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most individuals develop bone pain in the back or chest, or less commonly, the arms and legs, at the time of diagnosis. The pain is usually triggered by movement and is absent at night, except when changing positions.",
"    </p>",
"    <p>",
"     MM causes both generalized bone loss throughout the body as well as areas of bone destruction (called \"lytic lesions\" on x-ray) in specific areas. The bone loss and erosions can lead to osteoporosis and fractures. Many individuals with multiple myeloma experience fractures of the vertebrae (the bones of the spine), which can lead to a loss of height; about 30 percent of individuals experience fractures in other bones, often with little or no preceding trauma. For this reason they are called \"pathologic fractures.\"",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      High blood calcium levels",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because bones contain large amounts of calcium, the breakdown of bone in MM can lead to high blood calcium levels (called hypercalcemia). High blood calcium levels occur in 10 to 15 percent of individuals, and the symptoms may include loss of appetite, nausea, vomiting, frequent urination, increased thirst, constipation, weakness, confusion, stupor, or coma.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Anemia",
"     </span>",
"     &nbsp;&mdash;&nbsp;About two-thirds of individuals have anemia (low red cell count) at the time of diagnosis, and anemia eventually occurs in almost all individuals. The signs and symptoms of anemia include paleness, weakness, and fatigue.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Impaired kidney function",
"     </span>",
"     &nbsp;&mdash;&nbsp;The excess proteins and high blood calcium levels associated with MM can damage the kidneys. Kidney function is abnormal at diagnosis in about half of individuals with multiple myeloma. Occasionally, kidney failure is the first sign of MM.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Thickened blood",
"     </span>",
"     &nbsp;&mdash;&nbsp;The excessive production of proteins by the malignant plasma cells in MM can cause a thickening of the blood (called hyperviscosity syndrome). The symptoms may include bleeding from the nose and mouth, blurred vision, neurologic symptoms, and heart failure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Neurologic symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fractures of the vertebrae can lead to increased pressure on the nerve roots where they exit the spine, causing neurologic symptoms (called radiculopathy). This complication of multiple myeloma most commonly affects the chest, lower back, or legs, and the symptoms may include odd sensations (numbness or tingling), pain, or muscle weakness.",
"    </p>",
"    <p>",
"     Occasionally, neurologic symptoms occur because plasma cells grow within the spinal canal and press on the spinal cord. The symptoms may include severe back pain, muscle weakness, especially of the legs, numbness or tingling, and loss of control of bowel or bladder function (incontinence). Spinal cord compression is a medical emergency and requires immediate treatment to relieve the pressure and prevent permanent damage.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Generalized symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;The generalized symptoms of MM include an increased susceptibility to infections (especially during chemotherapy) and weight loss. Occasionally, it causes increased bleeding or tumors of the ribs. In individuals with advanced MM, tumor cells may accumulate beneath the skin, causing large purple-colored bumps.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      MULTIPLE MYELOMA TESTING",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of MM is based upon the presence of characteristic signs and symptoms of the disease and on the results of tests of the blood and bone marrow. Several tests are used to determine the presence and severity of MM. In some individuals with early MM or related conditions, it may be necessary to repeat these tests periodically until the diagnosis is certain.",
"    </p>",
"    <p>",
"     After MM is confirmed, additional tests are used to check for the presence of impaired kidney function, anemia, thickening of the blood, and other complications of multiple myeloma.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Blood and urine tests for monoclonal protein",
"     </span>",
"     &nbsp;&mdash;&nbsp;An abnormal protein produced by the plasma cells, called a monoclonal (M) protein (sometimes called a \"paraprotein\"), can be found in the blood or urine of almost all patients with MM, which helps establish the diagnosis. M proteins serve no useful function, and may be responsible for increases in the thickness of the blood, kidney damage, or bleeding problems.",
"    </p>",
"    <p>",
"     However, it is important to remember that not everyone with a monoclonal protein has MM. The diagnosis also requires one or more abnormalities such as anemia, bone lesions (see",
"     <a class=\"local\" href=\"#H13\">",
"      'X-rays'",
"     </a>",
"     below), kidney failure, or high calcium levels in the blood (see",
"     <a class=\"local\" href=\"#H16\">",
"      'Criteria for diagnosis'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Bone marrow examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most individuals with MM, a bone marrow aspiration and biopsy (a collection of a small sample of bone marrow for laboratory analysis, usually taken from the hip) shows that plasma cells comprise an abnormally high percentage of bone marrow cells (more than 10 percent). It may be necessary to collect samples from different areas because MM can affect the marrow of some bones but not others.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      X-rays",
"     </span>",
"     &nbsp;&mdash;&nbsp;In about 80 percent of individuals, routine x-rays show distinct, round (lytic) areas of bone erosion; generalized thinning of the bones;",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     fractures at the time of diagnosis. The bones most commonly involved are the vertebrae, the ribs, the pelvic bones, and the bones of the thigh and upper arm.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Genetic and chromosomal tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Specialized tests may reveal genetic or chromosomal abnormalities of the plasma cells in individuals with MM. The results of these tests are helpful for predicting the response to treatment and survival.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Plasma cell labeling index",
"     </span>",
"     &nbsp;&mdash;&nbsp;The plasma cell labeling index (PCLI) determines how rapidly the abnormal plasma cells are growing and dividing. Patients in whom the labeling index is low tend to have slower disease progression than those with high values. This test is also useful for distinguishing MM from related conditions that generally have a better prognosis. A normal plasma cell labeling index suggests that MM is less likely, while an elevated index suggests that multiple myeloma is more likely. Although this test is not readily available in many centers, PLCI is a reliable marker of high risk disease. Thus, if it is available, it is recommended to help differentiate between high risk and standard risk MM.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Criteria for diagnosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The diagnosis of multiple myeloma requires the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A bone marrow aspirate or biopsy showing that at least 10 percent of the cells are plasma cells or the presence of a plasma cell tumor (called a plasmacytoma),",
"       <strong>",
"        plus",
"       </strong>",
"      </li>",
"      <li>",
"       M protein in the blood or urine,",
"       <strong>",
"        plus",
"       </strong>",
"      </li>",
"      <li>",
"       Evidence of damage to the body as a result of the plasma cell growth, such as destructive bone lesions, kidney failure, anemia, or high calcium in the blood.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      MULTIPLE MYELOMA STAGING AND PROGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The simplest measure of prognosis in MM is based on blood levels of two markers: beta-2-microglobulin and albumin. In general, higher levels of beta-2-microglobulin and lower levels of albumin are associated with a poorer prognosis. This staging system is referred to as the International Staging System, or ISS.",
"    </p>",
"    <p>",
"     The Durie-Salmon staging system is an older system that divides patients into three stages: Stages I, II, and III, corresponding to low, intermediate, and high cell mass, depending upon the severity of anemia, calcium level, kidney function, presence or absence of bone lesions, and the quantity of abnormal proteins. This staging system is best used as a measure of the overall amounts of malignant plasma cells present in the patient, and is less useful as a measure of prognosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Standard versus high-risk MM",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately 25 percent of people with MM have high-risk disease. This type of MM is aggressive and may shorten survival. As such, patients with high risk disease are treated with more aggressive therapy.",
"    </p>",
"    <p>",
"     Tests performed to distinguish between high and standard risk MM include studies looking for chromosomal abnormalities and the plasma cell labeling index (PLCI).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      MULTIPLE MYELOMA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of multiple myeloma is discussed in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"      \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498669556\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5520754\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/26/29090?source=see_link\">",
"      Patient information: Multiple myeloma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/23/16754?source=see_link\">",
"      Patient information: Monoclonal gammopathy of undetermined significance (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5520762\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=see_link\">",
"      Allogeneic hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16662?source=see_link\">",
"      Diagnosis and management of solitary extramedullary plasmacytoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44535?source=see_link\">",
"      Diagnosis and management of solitary plasmacytoma of bone",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31526?source=see_link\">",
"      Evaluating response to treatment of multiple myeloma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=see_link\">",
"      Pathobiology of multiple myeloma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22551?source=see_link\">",
"      Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30409?source=see_link\">",
"      Treatment of kidney disease in multiple myeloma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/\">",
"      www.cancer.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Leukemia &amp; Lymphoma Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.leukemia-lymphoma.org/\">",
"      www.leukemia-lymphoma.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Marrow Donor Program",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.marrow.org/\">",
"      www.marrow.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?12/16/12547/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 16, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?12/16/12547?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12547/abstract/1\">",
"      Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12547/abstract/2\">",
"      UK myeloma forum. British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 115:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12547/abstract/3\">",
"      Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111:2962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12547/abstract/4\">",
"      Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 1992; 6:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12547/abstract/5\">",
"      Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12547/abstract/6\">",
"      Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011; 118:3205.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f12_16_12547=[""].join("\n");
var outline_f12_16_12547=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           MULTIPLE MYELOMA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           MULTIPLE MYELOMA FEATURES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           MULTIPLE MYELOMA TESTING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           MULTIPLE MYELOMA STAGING AND PROGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           MULTIPLE MYELOMA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f12_16_12548="Sorbitol: Patient drug information";
var content_f12_16_12548=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sorbitol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     see \"Sorbitol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"     see \"Sorbitol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702951",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sorbitol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695462",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with juice, milk, water, or sweet foods to make it taste better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use enema rectally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12125 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-D3C9B8B2AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12548=[""].join("\n");
var outline_f12_16_12548=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023575\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023577\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023576\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023581\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023582\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023584\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023579\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023580\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023585\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023586\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=related_link\">",
"      Sorbitol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=related_link\">",
"      Sorbitol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_16_12549="AbobotulinumtoxinA (botulinum toxin type A, Dysport): Drug information";
var content_f12_16_12549=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   AbobotulinumtoxinA (botulinum toxin type A, Dysport): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/50/41764?source=see_link\">",
"    see \"AbobotulinumtoxinA (botulinum toxin type A, Dysport): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9605326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7999220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dysport&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7999304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Neuromuscular Blocker Agent, Toxin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9605588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cervical dystonia:",
"     </b>",
"     I.M.: Initial: 500 units divided among affected muscles in toxin-na&iuml;ve or toxin-experienced patients. May re-treat at intervals of &ge;12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Dosage adjustments:",
"     </i>",
"     Adjust dosage in 250-unit increments; do not administer at intervals &lt;12 weeks; dosage range used in studies: 250-1000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Glabellar lines:",
"     </b>",
"     Adults &lt;65 years: I.M.: Inject 10 units (0.05 mL or 0.08 mL) into each of 5 sites (2 injections in each corrugator muscle and 1 injection in the procerus muscle) for a total dose of 50 units; do not administer at intervals &lt;3 months; efficacy has been demonstrated up to 4 repeated administrations",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9605589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cervical dystonia:",
"     </b>",
"     Refer to adult dosing. No specific adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Glabellar lines:",
"     </b>",
"     Not recommended in patients &ge;65 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9605590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9605591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9605595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dysport&trade;: 500 units [contains albumin (human), lactose 2.5 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9605328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9605327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM165110.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM165110.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9605593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cervical dystonia: Use 23- or 25-gauge needle to administer intramuscularly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glabellar lines: Use a 30-gauge needle to administer intramuscularly. Inject into each of 5 sites (2 injections in each corrugator muscle and 1 in the procerus muscle). Ensure injected volume/dose is accurate and where feasible keep to a minimum. Avoid injection near the levator palpebrae superioris. Medial corrugator injections should be at least 1 cm above the bony supraorbital ridge. Do not inject toxin closer than 1 cm above the central eyebrow.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7999305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cervical dystonia in both toxin-naive and previously treated patients; temporary improvement in the appearance of moderate-severe glabellar lines associated with procerus and corrugator muscle activity",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7999218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Botulinum products are not interchangeable; potency differences may exist between the products.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9605446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      &gt;10%:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Cervical dystonia:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dysphonia (&le;28%), fatigue (12%), headache (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dysphagia (15% to 39%), xerostomia (13% to 39%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site discomfort/pain (5% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (11% to 56%), facial paresis (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Eye disorders (&le;17%, includes accommodation disorder, blurred vision, diplopia, dryness, pain, pruritus, visual acuity decreased)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      1% to 10%:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Cervical dystonia:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Heart rate decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Blood glucose increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Pain (7%), muscle atrophy (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Breathing difficulties/dyspnea (~3%; onset: ~1 week; duration: ~3 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antibody formation (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Glabellar lines:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Contact dermatitis (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site pain/reaction (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Eyelid edema (2%), eyelid ptosis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Hematuria (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (10%), upper respiratory tract infection (3%), cough (2% to 3%), pharyngolaryngeal pain (2% to 3%), bronchitis (2% to 3%), sinusitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Any indication:",
"     </b>",
"     &lt;1% (Limited to important or life-threatening):  Amyotrophy, antibody formation, blurred vision, burning sensation, diplopia, dizziness, dysphagia, facial paresis, hypersensitivity, hypoesthesia, erythema, granulation tissue formation (excessive), malaise, photophobia, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9605334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to botulinum toxin or any component of the formulation, including milk protein; infection at the proposed injection site(s)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9605335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions may occur rarely; immediate treatment (including epinephrine 1:1000) should be available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antibody formation: Higher doses or more frequent administration may result in neutralizing antibody formation and loss of efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular events: Rarely, arrhythmia and myocardial infarction have been reported with use of onabotulinumtoxinA (another botulinum toxin formulation), sometimes in patients with preexisting cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dysphagia: Common when used for cervical dystonia and may persist anywhere from 2 weeks up to 5 months after administration. In severe cases, patients may require alternative feeding methods. Risk factors include smaller neck muscle mass, bilateral injections into the sternocleidomastoid muscle, or injections into the levator scapulae.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Systemic toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Distant spread of botulinum toxin beyond the site of injection has been reported; dysphagia and breathing difficulties have occurred and may be life threatening; other symptoms reported include blurred vision, diplopia, dysarthria, dysphonia, generalized muscle weakness, ptosis, and urinary incontinence which may develop within hours or weeks following injection.",
"     </b>",
"     Risk likely greatest in children treated for the unapproved use of spasticity. Systemic effects have occurred following use in approved and unapproved uses, including low doses. Immediate medical attention required if respiratory, speech, or swallowing difficulties appear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neuromuscular disease: Use with caution in patients with neuromuscular diseases (eg, myasthenia gravis, Eaton-Lambert syndrome) and neuropathic disorders (eg, amyotrophic lateral sclerosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular diseases: Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure and ulceration when treating blepharospasm. Retrobulbar hemorrhages may occur from needle penetration into orbit when treating strabismus; spatial disorientation, double vision, or past-pointing may occur if one or more extraocular muscles are paralyzed. Covering the affected eye may help. Careful testing of corneal sensation, avoidance of lower lid injections, and treatment of epithelial defects are necessary. Use caution in patients with angle closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Respiratory disease: Use extreme caution in patients with pre-existing respiratory disease; treatment of cervical dystonia using botulinum toxin may weaken accessory muscles that are necessary for these patients to maintain adequate ventilation. Risk of aspiration resulting from severe dysphagia is increased in patients with decreased respiratory function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neuromuscular transmission: Use with extreme caution in patients receiving other agents that may interfere with neuromuscular transmission (eg, aminoglycosides, neuromuscular-blocking agents).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Albumin: Product contains albumin and may carry a remote risk of virus transmission.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Lactose: Product contains lactose; do not administer to patients allergic to cow&rsquo;s milk protein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Product interchangeability: Botulinum products (abobotulinumtoxinA, onabotulinumtoxinA, rimabotulinumtoxinB) are not interchangeable; potency units are specific to each preparation and cannot be compared or converted to any other botulinum product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Temporary reduction in glabellar lines: Efficacy was not observed in older adults (&ge;65 years of age) and an increased frequency of ocular adverse events was reported in older adults compared to younger adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Chronic therapy: Long-term effects of chronic therapy unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Injection site: Use with caution if there is excessive weakness or atrophy at the proposed injection site(s); use is contraindicated if infection is present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperhidrosis: Safety in the treatment of hyperhidrosis has not been established. The possibility of an immune reaction resulting from an intradermal injection is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Temporary reduction in glabellar lines: Appropriate use: Do not use more frequently than every 3 months. Patients with marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin, or the inability to substantially lessen glabellar lines by physically spreading them apart were excluded from clinical trials. Use with caution in patients with surgical alterations to the facial anatomy. Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure and ulceration. Spatial disorientation, double vision, or past pointing may occur if one or more extraocular muscles are paralyzed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9349502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: AbobotulinumtoxinA may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: May enhance the adverse neuromuscular effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: AbobotulinumtoxinA may enhance the adverse neuromuscular effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9605330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9605331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryo-fetal toxicity has been observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if benefits justify the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9605333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9605592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains lactose; patients allergic to cow&rsquo;s milk protein should not receive product.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Dysport Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 unit (1): $511.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 unit (1): $852.00",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9605472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     AbobotulinumtoxinA (previously known as botulinum toxin type A) is a neurotoxin produced by",
"     <i>",
"      Clostridium botulinum",
"     </i>",
"     , spore-forming anaerobic bacillus, which appears to affect only the presynaptic membrane of the neuromuscular junction in humans, where it prevents calcium-dependent release of acetylcholine and produces a state of denervation. Muscle inactivation persists until new fibrils grow from the nerve and form junction plates on new areas of the muscle-cell walls.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9605474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Peak effect: Cervical dystonia: 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Cervical dystonia: Up to 4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Not expected to be present in peripheral blood at recommended doses following intramuscular (I.M.) injection",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9195 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12549=[""].join("\n");
var outline_f12_16_12549=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605326\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7999220\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7999304\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605588\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605589\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605590\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605591\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605595\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605328\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605327\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605593\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7999305\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7999218\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605446\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605334\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605335\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298630\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349502\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605330\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605331\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605333\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605592\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322606\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605472\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605474\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9195\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9195|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/50/41764?source=related_link\">",
"      AbobotulinumtoxinA (botulinum toxin type A, Dysport): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_16_12550="Traumatic urethral injury";
var content_f12_16_12550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Traumatic urethral injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12550=[""].join("\n");
var outline_f12_16_12550=null;
var title_f12_16_12551="Insulin lispro protamine and insulin lispro: Drug information";
var content_f12_16_12551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin lispro protamine and insulin lispro: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/37/9813?source=see_link\">",
"    see \"Insulin lispro protamine and insulin lispro: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/19/3382?source=see_link\">",
"    see \"Insulin lispro protamine and insulin lispro: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2176667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumaLOG&reg; Mix 50/50&trade;;",
"     </li>",
"     <li>",
"      HumaLOG&reg; Mix 50/50&trade; KwikPen&trade;;",
"     </li>",
"     <li>",
"      HumaLOG&reg; Mix 75/25&trade;;",
"     </li>",
"     <li>",
"      HumaLOG&reg; Mix 75/25&trade; KwikPen&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2186198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humalog&reg; Mix 25",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2136142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Insulin, Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2138128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Lispro protamine is an intermediate-acting insulin and lispro is a rapid-acting insulin administered by SubQ injection. Insulin lispro protamine and insulin lispro combination products are approximately equipotent to insulin NPH and insulin regular combination products with a similar duration of activity but a more rapid onset. With combination insulin products, the proportion of rapid-acting to long-acting insulin is fixed; basal vs prandial dose adjustments cannot be made. Fixed ratio insulins (such as insulin lispro protamine and insulin lispro combination) are typically administered as 2 daily doses with each dose intended to cover two meals and a snack. Because of variability in the peak effect and individual patient variability in activities, meals, etc, it may be more difficult to achieve complete glycemic control using fixed combinations of insulins; frequent monitoring and close medical supervision may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of different insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined.",
"     </b>",
"     Insulin lispro protamine and insulin lispro combination product is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing of combination insulin products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     SubQ: 0.5-1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the daily insulin dose is given as an intermediate- or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin at the same time before breakfast and dinner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized. Also see Additional Information or Pharmacotherapy Pearls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 2:",
"     </b>",
"     SubQ: Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate):",
"     <b>",
"      Note:",
"     </b>",
"     Insulin lispro protamine and insulin lispro combination product is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing of combination insulin products. Dosage must be carefully adjusted.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2138129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8103705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HumaLOG&reg; Mix 50/50&trade;: Insulin lispro protamine suspension 50% [intermediate acting] and insulin lispro solution 50% [rapid acting]: 100 units/mL  (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HumaLOG&reg; Mix 50/50&trade; KwikPen&trade;: Insulin lispro protamine suspension 50% [intermediate acting] and insulin lispro solution 50% [rapid acting]: 100 units/mL (3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HumaLOG&reg; Mix 75/25&trade;: Insulin lispro protamine suspension 75% [intermediate acting] and insulin lispro solution 25% [rapid acting]: 100 units/mL  (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HumaLOG&reg; Mix 75/25&trade; KwikPen&trade;: Insulin lispro protamine suspension 75% [intermediate acting] and insulin lispro solution 25% [rapid acting]: 100 units/mL (3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2345303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2137985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ administration: In order to properly resuspend the insulin, vials should be carefully shaken or rolled several times and prefilled pens should be rolled between the palms ten times and inverted 180&deg; ten times. Properly resuspended insulin should look uniformly cloudy or milky; do not use if any white insulin substance remains at the bottom of the container, if any clumps are present, if the insulin remains clear after adequate mixing, or if white particles are stuck to the bottom or wall of the container. Cold injections should be avoided. Insulin lispro protamine and insulin lispro combination products should be administered within 15 minutes before a meal; typically given once- or twice daily. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites. Do not dilute or mix with any other insulin formulation or solution;",
"     <b>",
"      not",
"     </b>",
"     recommended for use in external SubQ insulin infusion pump.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2138119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Insulin aspart, insulin detemir, insulin glargine, insulin glulisine, insulin NPH, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2138107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2137984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HumaLOG&reg; Mix 50/50&trade; may be confused with HumaLOG&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HumaLOG&reg; Mix 75/25&trade; may be confused with HumuLIN&reg; 70/30, NovoLIN&reg; 70/30, and NovoLOG&reg; Mix 70/30",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2345306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2138087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; during episodes of hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2138113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Insulin (especially I.V. insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium and supplement potassium when necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Insulin lispro protamine and insulin lispro premixed combination products are",
"     <b>",
"      NOT",
"     </b>",
"     intended for I.V. or I.M. administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- [insulin lispro protamine and insulin lispro] or long-acting insulin via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8103651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2345309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2345311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Use caution with ethanol; may increase risk of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Use caution with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle; may increase risk of hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2138108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2138109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Insulin lispro has not been shown to cross the placenta at standard clinical doses. Although congenital anomalies have been noted in case reports, when compared to regular insulin, insulin lispro has not been found to increase the risk of adverse events to the fetus in larger studies. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy. The use of insulin lispro has been shown to be as effective as regular insulin to treat diabetes in pregnancy and may have advantages over regular insulin during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2138111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/compatible",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2138112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if significant amounts of insulin lispro distribute into breast milk. Endogenous insulin can be found in breast milk. Plasma glucose concentrations in the mother affect glucose concentrations in breast milk. The gastrointestinal tract destroys insulin when administered orally; therefore, insulin is not expected to be absorbed intact by the breast-feeding infant. All types of insulin are safe for use while breast-feeding. Due to increased calorie expenditure, women with diabetes may require less insulin while nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2345312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (HumaLOG Mix 50/50 KwikPen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (50-50) 100 units/mL (3 mL): $65.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (HumaLOG Mix 50/50 Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (50-50) 100 units/mL (10 mL): $168.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (HumaLOG Mix 75/25 KwikPen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (75-25) 100 units/mL (3 mL): $65.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (HumaLOG Mix 75/25 Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (75-25) 100 units/mL (10 mL): $168.48",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8103706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diabetes mellitus: Plasma glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F6258746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic, serum insulin (fasting): 5-20 &mu;IU/mL (SI: 35-145 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elderly: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes mellitus (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak postprandial capillary plasma glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Humalog 25 (CL);",
"     </li>",
"     <li>",
"      Humalog Mix (AT, BE, CH, DE, DK, EE, ES, FR, GB, GR, IL, NO, PT, RU, SE, TR, TW);",
"     </li>",
"     <li>",
"      Humalog Mix 25 (AU, BB, BM, BR, BS, BZ, CN, CO, CR, DO, GT, GY, HK, HN, ID, IL, JM, KP, MX, MY, NI, NL, NZ, PA, PE, PH, PR, SG, SR, SV, TH, TT, VE);",
"     </li>",
"     <li>",
"      Humalog Mix 50 (AU, IL);",
"     </li>",
"     <li>",
"      Humalog NPL (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2138120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin lispro protamine and insulin lispro is an intermediate-acting combination product with a more rapid onset and similar duration of action as compared to that of insulin NPH and insulin regular combination products.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2138122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Rate of absorption, onset, and duration of activity may be affected by site of injection, exercise, presence of lipodystrophy, local blood supply, and/or temperature.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Onset of action: 0.25-0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Humalog&reg; Mix 50/50&trade;: 0.8-4.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Humalog&reg; Mix 75/25&trade;: 1-6.5 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Duration: 14-24 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Time to peak, plasma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Humalog&reg; Mix 50/50&trade;: 0.75-13.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Humalog&reg; Mix 75/25&trade;: 0.5-4 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12551/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12551/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies M, Storms F, Shutler S, et al, &ldquo;Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(6):1282-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12551/abstract-text/15920040/pubmed\" id=\"15920040\" target=\"_blank\">",
"        15920040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meneghini L, Koenen C, Rojas P, et al, &ldquo;Efficacy and Safety of Insulin Detemir in a Large Cohort of Patients With Type 2 Diabetes Using a Simplified Self-Adjusted Dosing Guideline -- Results of the Predictive 303 Study,&rdquo; Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-25, 2007; Chicago, Ill.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse, JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12551/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12551/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riddle MC, Rosenstock J, and Gerich J, &ldquo;The Treat-To-Target Trial,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2003, 26(11):3080-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12551/abstract-text/14578243/pubmed\" id=\"14578243\" target=\"_blank\">",
"        14578243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12551/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein J, Klingensmith G, Copeland K, et al, &ldquo;Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,&rdquo;",
"      <i>",
"       Diabetes Care,",
"      </i>",
"      2005, 28(1):186-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12551/abstract-text/15616254/pubmed\" id=\"15616254\" target=\"_blank\">",
"        15616254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9027 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.124.72.62-40C0DE6EA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12551=[""].join("\n");
var outline_f12_16_12551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2176667\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2186198\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136142\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138128\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062821\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138129\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103705\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104239\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2345303\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137985\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138119\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138107\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137984\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2345306\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138087\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138113\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103651\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2345309\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2345311\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138108\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138109\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138111\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138112\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2345312\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422167\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103706\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6258746\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869461\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138120\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138122\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9027\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9027|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/37/9813?source=related_link\">",
"      Insulin lispro protamine and insulin lispro: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/19/3382?source=related_link\">",
"      Insulin lispro protamine and insulin lispro: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_16_12552="Endoscopic ultrasound-guided fine-needle aspiration in the mediastinum";
var content_f12_16_12552=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic ultrasound-guided fine-needle aspiration in the mediastinum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/16/12552/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/16/12552/contributors\">",
"     Julia Kim LeBlanc, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/16/12552/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/16/12552/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/16/12552/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/16/12552/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/16/12552/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound (EUS) is a combination of endoscopy and ultrasonography. It is an effective and safe method of examining the posterior mediastinum, although it was initially developed as a method of evaluating the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EUS should be distinguished from endobronchial ultrasound (EBUS). Both visualize and guide sampling of mediastinal lymph nodes, but EUS is performed during endoscopy and EBUS is performed during bronchoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43427?source=see_link\">",
"     \"Endobronchial ultrasound: Technical aspects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=see_link\">",
"     \"Endobronchial ultrasound: Indications, advantages, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The procedure and its indications are discussed in this topic review. In addition, the advantages, disadvantages, and complications of EUS are reviewed. Overviews of the evaluation of mediastinal masses and the staging of NSCLC are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link\">",
"     \"Evaluation of mediastinal masses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=see_link\">",
"     \"Diagnosis and staging of non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound (EUS) is performed with an echoendoscope (an endoscope with an ultrasound transducer engineered into its tip). The echoendoscope is flexible, approximately 13 mm in diameter, and can obtain reliable images at a depth ranging from 3 mm to 8 cm from the transducer. Two types of echoendoscopes exist, radial and curvilinear. The radial echoendoscope provides a 360-degree ultrasound image of the gastrointestinal tract and surrounding structures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76193 \" href=\"UTD.htm?26/34/27183\">",
"     image 1",
"    </a>",
"    ). In contrast, the curvilinear echoendoscope provides a 180-degree view that is parallel to the shaft of the echoendoscope, thereby allowing real-time visualization of fine needle aspiration. Color flow and Doppler features of the curvilinear echoendoscope permit identification of vascular, ductular, and cystic structures.",
"   </p>",
"   <p>",
"    The procedure begins once the patient is adequately sedated. The radial echoendoscope is passed through the mouth until the tip reaches the duodenum, and then withdrawn slowly in 1 to 2 cm increments while ultrasound imaging is performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The upper retroperitoneum is visualized through the gastric wall, including the retroperitoneal lymph nodes, left adrenal gland, left lobe of the liver, and other retroperitoneal structures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"       \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The posterior mediastinum is visualized through the esophageal wall. The heart, pleura, spine, and vascular structures can be readily identified. In addition, mediastinal lymph nodes may be visualized in the subcarina (level 7), the paraesophageal area (levels 8), adjacent to the inferior pulmonary ligament (level 9), and, possibly, the aortopulmonary window (level 5) (",
"      <a class=\"graphic graphic_figure graphicRef63771 \" href=\"UTD.htm?0/10/167\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef73945 \" href=\"UTD.htm?19/28/19914\">",
"       figure 2",
"      </a>",
"      ). Abnormalities may also be detected in the paratracheal areas (levels 2 and 4) and adjacent to the ascending aorta (level 6) if they are large enough.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The radial echoendoscope is withdrawn and a curvilinear echoendoscope is advanced to the desired location if fine needle aspiration (FNA) will be performed. The curvilinear echoendoscope is used for the aspiration. The duration of the procedure is typically 30 to 60 minutes. It is usually performed as an outpatient procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fine needle aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS can provide real-time ultrasonographic guidance for FNA of posterior mediastinal and upper retroperitoneal lesions and lymph nodes (EUS-FNA) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. A 22-gauge fine aspiration needle is passed through the working channel of a curvilinear echoendoscope and into the target. Aspiration is then performed. Following removal of the aspiration needle, air is forced through the needle with a 10 mL air-filled syringe, which expels the aspirated sample onto a glass slide. Two direct smears are usually made from one aspirate; one slide is dried with 0.95 alcohol, while the other slide is stained for immediate on-site interpretation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76828 \" href=\"UTD.htm?26/31/27135\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The importance of histologic confirmation of malignant or benign mediastinal disease cannot be overstated. Ultimately, patient management is impacted. As an example, surgery and other invasive sampling methods may be avoided if small cell lung cancer, lymphoma, or benign disease is confirmed by EUS-FNA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/4,6-13\">",
"     4,6-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary indications for endoscopic ultrasound (EUS) are diagnostic sampling of mediastinal abnormalities and staging of non-small cell lung cancer.",
"   </p>",
"   <p>",
"    Diagnostic sampling of mediastinal abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For mediastinal abnormalities (eg, lymphadenopathy or mass) that need to be sampled, we believe EUS-guided fine needle aspiration (EUS-FNA) should be the first sampling method performed when the target lesion appears accessible and is paraesophageal, in the posterior mediastinum, or in the inferior mediastinum [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For mediastinal abnormalities in the anterior or superior mediastinum, endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TBNA) may be a more appropriate initial sampling method. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=see_link\">",
"       \"Endobronchial ultrasound: Indications, advantages, and complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In centers where neither EUS-FNA nor EBUS-TBNA is available, mediastinoscopy or thoracoscopy may be the preferred approach for diagnosing mediastinal abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The staging of non-small cell lung cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=see_link\">",
"     \"Diagnosis and staging of non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) can be used to diagnose benign and malignant disease in the mediastinum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Benign diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive lymphadenopathy and the granulomatous diseases (eg, sarcoidosis, tuberculosis, histoplasmosis) are among the benign conditions that can manifest mediastinal lymphadenopathy. EUS-FNA is a safe alternative to other diagnostic methods (eg, mediastinoscopy) and has a high diagnostic yield in patients with benign mediastinal disease if the pretest probability is high [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective cohort study of 127 patients who had mediastinal lymphadenopathy of unknown cause, EUS-FNA identified sarcoidosis with a sensitivity and specificity of 89 and 96 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In retrospective cohort study of 49 patients who had a mediastinal mass, no history of pulmonary malignancy, and underwent EUS-FNA, benign diseases were detected in 24 patients (49 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/21\">",
"       21",
"      </a>",
"      ]. They included histoplasmosis (eight patients), sarcoidosis (one patient), leiomyoma (two patients), duplication cyst (two patients), teratoma (one patient), and benign lymphadenopathy (ten patients).",
"     </li>",
"     <li>",
"      In a prospective cohort study, 50 patients with suspected sarcoidosis underwent EUS-FNA [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/16\">",
"       16",
"      </a>",
"      ]. Sarcoidosis was confirmed in 41 patients (82 percent). Among the patients who had granulomas detected by EUS-FNA, 71 percent had a prior non-diagnostic bronchoscopy. Aspirated lymph nodes were in the paratracheal, aortopulmonary window, and paraesophageal regions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A sample aspirate from a patient with sarcoidosis is shown in the figure (",
"    <a class=\"graphic graphic_picture graphicRef54916 \" href=\"UTD.htm?16/35/16951\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Malignant diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS-FNA is also a valuable tool for detecting malignant disease in the mediastinum. Lung cancer is the most common type of malignant mediastinal disease, but other types of malignant disease can also occur in the mediastinum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy is often the first invasive diagnostic test performed when lung cancer is suspected. However, bronchoscopy fails to make a diagnosis in up to 30 percent of such patients. EUS-FNA is a valuable diagnostic tool in this situation, especially if there is lymphadenopathy in the posterior or inferior mediastinum.",
"   </p>",
"   <p>",
"    In a prospective cohort study of 35 patients suspected of having lung cancer but whose bronchoscopy was nondiagnostic, EUS-FNA correctly detected lung cancer in 25 of the 26 patients who had lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/7\">",
"     7",
"    </a>",
"    ]. The remaining nine patients had benign disease. The diagnoses were obtained by EUS-FNA of high paratracheal (level 2), aortopulmonary window (level 5), subcarinal (level 7), paraesophageal (level 8), or hilar (level 10) lymph nodes. Some of the lymph nodes were less than 1 cm; thus, sampling by alternative nonsurgical methods would have been difficult if not impossible. Other studies have demonstrated similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS-FNA is also an effective technique for detecting malignant mediastinal diseases other than lung cancer. A retrospective cohort study evaluated 49 patients in whom lung cancer was not suspected but who underwent EUS-FNA to evaluate mediastinal lymphadenopathy or a mediastinal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/21\">",
"     21",
"    </a>",
"    ]. EUS-FNA identified malignant mediastinal disease in 22 patients (45 percent). Diagnoses included breast cancer (six patients), colon cancer (two patients), renal cell cancer (two patients), testicular cancer (two patients), esophageal cancer (one patient), laryngeal cancer (one patient), and metastatic disease from an unknown site (four patients). Lung cancer was also detected: NSCLC in two patients and small cell lung cancer in one patient (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64111 \" href=\"UTD.htm?17/59/18356\">",
"     image 3",
"    </a>",
"    ). When both malignant and benign diagnoses were considered, EUS-FNA made the correct diagnosis in 94 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     STAGING NSCLC",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSCLC is usually staged according to the tumor-node-metastasis (TNM) system. This system takes into account the characteristics of the local tumor (T), the presence or absence of regional lymph node metastasis (N), and the presence or absence of distant metastases (M). The stage of the tumor (stage I through IV) depends upon the particular combination of T, N, and M characteristics for the given patient. The 7th edition of the TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ) is the most recent version, replacing the 6th edition (",
"    <a class=\"graphic graphic_table graphicRef74820 \" href=\"UTD.htm?19/43/20157\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68104 \" href=\"UTD.htm?13/4/13388\">",
"     table 3",
"    </a>",
"    ) as of January 1, 2010. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of up to 95 percent of patients may be impacted when endoscopic ultrasound (EUS) is used to stage NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/9,11,22-28\">",
"     9,11,22-28",
"    </a>",
"    ]. In a prospective cohort study of 84 patients with known or suspected lung cancer plus a mediastinal lesion who underwent EUS-guided fine needle aspiration (EUS-FNA), thoracotomy or thoracoscopy became unnecessary in 49 percent of patients and mediastinoscopy became unnecessary in 68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, EUS-FNA was more cost effective than either surgical staging method.",
"   </p>",
"   <p>",
"    EUS can contribute to each component of TNM staging. In other words, it can help characterize the primary tumor, assess the mediastinal lymph nodes for evidence of metastatic disease, and evaluate some sites of distant metastasis such as the left lobe of the liver and adrenal glands. Among these contributions, however, mediastinal lymph node evaluation is its primary role. The implications of the disease stage on subsequent management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of stage III non-small cell lung cancer\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Primary tumor (T)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visualization of the primary tumor with EUS can identify tumor that invades mediastinal structures, such as the left atrium, aorta, centrally located pulmonary vessels, vertebra, and esophagus. This degree of tumor defines T4 in the TNM staging system and precludes curative surgery (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ). EUS detects tumor invasion of the mediastinal structures with a sensitivity and specificity of 87 and 98 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lymph nodes (N)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of metastasis to the hilar or mediastinal lymph nodes defines the N component in the TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ). Patients with either enlarged mediastinal lymph nodes by computed tomography (CT) or metabolically active mediastinal lymph nodes by positron emission tomography (PET) generally undergo lymph node sampling, because the sensitivity and specificity of imaging alone in the detection of lymph node metastasis are insufficient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=see_link\">",
"     \"Diagnosis and staging of non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EUS-FNA is effective at detecting metastatic disease. It can sample lymph nodes in the posterior mediastinum (levels 6, 8, and 9) and subcarina (level 7), sites that are particularly susceptible to metastasis. In addition, it might be able to sample lymph nodes in the aortopulmonary window (level 5), although this is controversial.",
"   </p>",
"   <p>",
"    Metastasis to mediastinal lymph nodes is identified by EUS-FNA with an accuracy (ie, weighted mean of sensitivity and specificity) of 83 to 97 percent and a sensitivity of 84 to 92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/4-8,21,23,24,27,30-33\">",
"     4-8,21,23,24,27,30-33",
"    </a>",
"    ]. This was illustrated by a prospective cohort study of 104 patients in which EUS-FNA detected malignant posterior mediastinal lymph nodes with a sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 92, 100, 100, 94, and 97 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EUS-FNA and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) are often combined because EBUS has better access to anterior and superior mediastinal lymph nodes, while EUS has better access to posterior and inferior mediastinal lymph nodes. In theory, the entire mediastinum is accessible to the combination of EUS-FNA plus EBUS-guided TBNA. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=see_link&amp;anchor=H4#H4\">",
"     \"Endobronchial ultrasound: Indications, advantages, and complications\", section on 'Regional lymph nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     No lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of EUS in staging patients who have NSCLC, but no enlarged mediastinal lymph nodes according to computed tomography (CT), is uncertain because most clinical experience and data are from patients with mediastinal lymphadenopathy. In theory, EUS-FNA might be beneficial even in the absence of enlarged mediastinal lymph nodes because such lymph nodes contain metastasis in up to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/2,34\">",
"     2,34",
"    </a>",
"    ]. Data are beginning to accumulate that support this belief:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective cohort study of 69 patients who had NSCLC without enlarged mediastinal lymph nodes, EUS-FNA detected advanced disease in 17 patients (25 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/28\">",
"       28",
"      </a>",
"      ]. This included metastasis to the mediastinal lymph nodes (14 patients), mediastinal invasion of the primary tumor (two patients), and metastasis to the adrenal gland (one patient). EUS-FNA detected advanced mediastinal disease with a sensitivity and specificity of 61 and 98 percent, respectively.",
"     </li>",
"     <li>",
"      In a prospective cohort study of 76 patients who had NSCLC without enlarged lymph nodes, EUS-FNA impacted the management of 18 patients (25 percent), which included the detection of advanced disease that precluded surgery in nine patients (12 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/26\">",
"       26",
"      </a>",
"      ]. The types of advanced disease detected included metastasis to contralateral mediastinal lymph nodes (eg, N3 disease), esophageal invasion (ie, T4 disease), metastasis to celiac lymph nodes, and synchronous esophageal cancer. Metastasis was more commonly detected in mediastinal lymph nodes when the primary tumor resided in the lower lobes, hila, or lingula.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Molecular analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Samples obtained from mediastinal lymph nodes by EUS-FNA can be used to detect lung cancer-associated genes, such as CEA, CK19,",
"    <span class=\"nowrap\">",
"     KS1/4,",
"    </span>",
"    lunx, muc 1, and PDEF. In one study, overexpression of the",
"    <span class=\"nowrap\">",
"     KS1/4",
"    </span>",
"    gene was associated with metastatic disease, even in cytology-negative lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/35\">",
"     35",
"    </a>",
"    ]. In another study, gene promoter hypermethylation predicted micrometastasis within mediastinal lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/36\">",
"     36",
"    </a>",
"    ]. The combined use of EUS-FNA and tumor markers may prove to be a useful predictor of occult metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Metastasis (M)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastasis to the celiac lymph nodes, left adrenal gland, and left lobe of the liver can be detected and sampled by EUS-FNA (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68097 \" href=\"UTD.htm?34/60/35778\">",
"     image 4",
"    </a>",
"    ). In one prospective cohort study of 113 patients with lung cancer, celiac lymphadenopathy was identified in 19 patients (11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/37\">",
"     37",
"    </a>",
"    ]. The diagnostic yield of EUS-FNA for detecting metastases to these lymph nodes was 100 percent, compared to only 50 percent for CT.",
"   </p>",
"   <p>",
"    Such lesions define M1 in the TNM staging system and preclude curative surgery. The ability to detect and sample abdominal lesions during a mediastinal staging procedure makes EUS-FNA an attractive modality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/12,26,27,38,39\">",
"     12,26,27,38,39",
"    </a>",
"    ]. All other modalities capable of evaluating the mediastinum for metastasis require a second procedure to evaluate potential metastatic disease in the abdomen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Restaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restaging may be desired following neoadjuvant therapy. EUS-FNA detected residual NSCLC in ipsilateral or subcarinal mediastinal lymph nodes with a sensitivity, specificity, and accuracy of 75, 100, and 83 percent respectively, after cisplatin-based chemotherapy in one prospective cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ADVANTAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) offers many advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EUS-FNA is often preferred by patients because it is painless, minimally invasive, can be performed on outpatient basis, and does not require general anesthesia.",
"     </li>",
"     <li>",
"      EUS-FNA can easily reach the posterior mediastinal lymph nodes. This is advantageous because the posterior mediastinal lymph nodes are a common site of lung cancer metastases and are inaccessible to most alternative staging modalities.",
"     </li>",
"     <li>",
"      EUS-FNA is performed with real-time ultrasonography, which permits the sampling of small lesions (as small as 3 mm) and minimizes the risk of pneumothorax or hemorrhage. The ability to sample small lymph nodes improves the sensitivity of NSCLC staging, which can prevent patients from undergoing unnecessary surgery or additional staging procedures.",
"     </li>",
"     <li>",
"      EUS-FNA can visualize and sample extrathoracic sites that are not accessible to other mediastinal staging modalities. As an example, the celiac lymph nodes, left adrenal gland, and left lobe of the liver can be sampled [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/26,27,38,41,42\">",
"       26,27,38,41,42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DISADVANTAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EUS-FNA cannot stage the entire mediastinum because it is unable to evaluate the anterior mediastinum due to air interference from the trachea.",
"     </li>",
"     <li>",
"      EUS-FNA can give false-negative results. This is the result of sampling error, which also exists with the other mediastinal staging modalities.",
"     </li>",
"     <li>",
"      EUS-FNA requires expertise, which is not widely available.",
"     </li>",
"     <li>",
"      Rarely, EUS-FNA can give false-positive results when the aspirated lymph node is adjacent to a mediastinal mass [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few contraindications to endoscopic ultrasound-guided fine needle aspiration (EUS-FNA), but those that exist include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who cannot tolerate routine conscious sedation. In such patients, an alternative staging modality should be chosen, or EUS-FNA should be performed with increased monitoring, such as in an operating room with an anesthesiologist.",
"     </li>",
"     <li>",
"      Esophageal obstruction.",
"     </li>",
"     <li>",
"      Bleeding disorders that cannot be corrected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complication rate of endoscopic ultrasound-guide fine needle aspiration (EUS-FNA) depends on the type of target lesion. In a prospective cohort study of 457 patients (554 lesions), complications were less frequent with solid lesions (eg, mediastinal masses, lymphadenopathy) than cystic lesions (0.5 versus 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reported complications of EUS-FNA of solid lesions include infection, hemorrhage, drug reaction, bowel wall perforation, and posterior pharyngeal perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/44\">",
"     44",
"    </a>",
"    ]. Pneumothorax and mediastinitis are theoretical risks of EUS-FNA in the mediastinum, but neither has been reported.",
"   </p>",
"   <p>",
"    Reported complications of EUS-FNA of mediastinal cysts include severe mediastinitis requiring thoracotomy and candidal fungal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. The latter remained asymptomatic until the planned surgery was performed.",
"   </p>",
"   <p>",
"    Mediastinal-esophageal fistula formation has been reported after EUS-FNA of mediastinal adenopathy that was tuberculosis in origin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12552/abstract/48\">",
"     48",
"    </a>",
"    ]. This finding was noted after the patient presented with odynophagia 3 days after the procedure. Symptoms resolved three months after instituting treatment for tuberculosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic ultrasound (EUS) is a combination of endoscopy and ultrasonography. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EUS is performed with an echoendoscope (an endoscope with an ultrasound transducer in its tip). EUS can provide real-time ultrasonographic guidance for fine needle aspiration (EUS-FNA). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EUS-FNA can visualize and sample abnormalities in the upper retroperitoneum and posterior mediastinum. Mediastinal lymph nodes that can be visualized include the aortopulmonary window (level 5), the subcarina (level 7), the paraesophageal area (levels 8), and adjacent to the inferior pulmonary ligament (level 9) (",
"      <a class=\"graphic graphic_figure graphicRef63771 \" href=\"UTD.htm?0/10/167\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef73945 \" href=\"UTD.htm?19/28/19914\">",
"       figure 2",
"      </a>",
"      ). Abnormalities may also be detected in the paratracheal areas (levels 2 and 4) and adjacent to the ascending aorta (level 6) if they are large enough. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EUS is not widely available. However, the following applies to centers that have expertise in EUS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      EUS-FNA is indicated for diagnostic sampling of mediastinal abnormalities (eg, lymphadenopathy or a mass) and staging of non-small cell lung cancer. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once it has been determined that a mediastinal sampling is necessary, we suggest that EUS-FNA be the first sampling procedure if the target lesion appears accessible and is paraesophageal, in the posterior, or in the inferior mediastinum and. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EUS-FNA has a high yield and accurately identifies both benign and malignant mediastinal disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Benign diseases'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Malignant diseases'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Staging NSCLC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall, EUS-FNA has many advantages and relatively few disadvantages or contraindications. Complications are uncommon and vary according to the type of lesion that is sampled. Reported complications include infection, hemorrhage, drug reaction, bowel wall perforation, posterior pharyngeal perforation, and mediastinitis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Advantages'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Disadvantages'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Contraindications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/1\">",
"      DiMagno EP, Buxton JL, Regan PT, et al. Ultrasonic endoscope. Lancet 1980; 1:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/2\">",
"      Kondo D, Imaizumi M, Abe T, et al. Endoscopic ultrasound examination for mediastinal lymph node metastases of lung cancer. Chest 1990; 98:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/3\">",
"      Hawes RH, Gress F, Kesler KA, et al. Endoscopic ultrasound versus computed tomography in the evaluation of the mediastinum in patients with non-small-cell lung cancer. Endoscopy 1994; 26:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/4\">",
"      Pedersen BH, Vilmann P, Folke K, et al. Endoscopic ultrasonography and real-time guided fine-needle aspiration biopsy of solid lesions of the mediastinum suspected of malignancy. Chest 1996; 110:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/5\">",
"      Silvestri GA, Hoffman BJ, Bhutani MS, et al. Endoscopic ultrasound with fine-needle aspiration in the diagnosis and staging of lung cancer. Ann Thorac Surg 1996; 61:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/6\">",
"      Wallace MB, Silvestri GA, Sahai AV, et al. Endoscopic ultrasound-guided fine needle aspiration for staging patients with carcinoma of the lung. Ann Thorac Surg 2001; 72:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/7\">",
"      Fritscher-Ravens A, Soehendra N, Schirrow L, et al. Role of transesophageal endosonography-guided fine-needle aspiration in the diagnosis of lung cancer. Chest 2000; 117:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/8\">",
"      Larsen SS, Krasnik M, Vilmann P, et al. Endoscopic ultrasound guided biopsy of mediastinal lesions has a major impact on patient management. Thorax 2002; 57:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/9\">",
"      Fritscher-Ravens A, Davidson BL, Hauber HP, et al. Endoscopic ultrasound, positron emission tomography, and computerized tomography for lung cancer. Am J Respir Crit Care Med 2003; 168:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/10\">",
"      Varadarajulu S, Hoffman BJ, Hawes RH, Eloubeidi MA. EUS-guided FNA of lung masses adjacent to or abutting the esophagus after unrevealing CT-guided biopsy or bronchoscopy. Gastrointest Endosc 2004; 60:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/11\">",
"      Savides TJ, Perricone A. Impact of EUS-guided FNA of enlarged mediastinal lymph nodes on subsequent thoracic surgery rates. Gastrointest Endosc 2004; 60:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/12\">",
"      Kramer H, Groen HJ. Diagnosis of mediastinal and left adrenal abnormalities with endoscopic ultrasonography. Respir Med 2005; 99:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/13\">",
"      Caddy G, Conron M, Wright G, et al. The accuracy of EUS-FNA in assessing mediastinal lymphadenopathy and staging patients with NSCLC. Eur Respir J 2005; 25:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/14\">",
"      ASGE Standards of Practice Committee, Jue TL, Sharaf RN, et al. Role of EUS for the evaluation of mediastinal adenopathy. Gastrointest Endosc 2011; 74:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/15\">",
"      Fritscher-Ravens A, Sriram PV, Topalidis T, et al. Diagnosing sarcoidosis using endosonography-guided fine-needle aspiration. Chest 2000; 118:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/16\">",
"      Annema JT, Veseli&ccedil; M, Rabe KF. Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of sarcoidosis. Eur Respir J 2005; 25:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/17\">",
"      Walsh PR, Williams DB. Mediastinal adenopathy: finding the answer with endoscopic ultrasound-guided fine-needle aspiration biopsy. Intern Med J 2005; 35:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/18\">",
"      Mishra G, Sahai AV, Penman ID, et al. Endoscopic ultrasonography with fine-needle aspiration: an accurate and simple diagnostic modality for sarcoidosis. Endoscopy 1999; 31:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/19\">",
"      Tournoy KG, Praet MM, Van Maele G, Van Meerbeeck JP. Esophageal endoscopic ultrasound with fine-needle aspiration with an on-site cytopathologist: high accuracy for the diagnosis of mediastinal lymphadenopathy. Chest 2005; 128:3004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/20\">",
"      Wildi SM, Judson MA, Fraig M, et al. Is endosonography guided fine needle aspiration (EUS-FNA) for sarcoidosis as good as we think? Thorax 2004; 59:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/21\">",
"      Devereaux BM, Leblanc JK, Yousif E, et al. Clinical utility of EUS-guided fine-needle aspiration of mediastinal masses in the absence of known pulmonary malignancy. Gastrointest Endosc 2002; 56:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/22\">",
"      Annema JT, Veseli&ccedil; M, Rabe KF. EUS-guided FNA of centrally located lung tumours following a non-diagnostic bronchoscopy. Lung Cancer 2005; 48:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/23\">",
"      Gress FG, Savides TJ, Sandler A, et al. Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography, and computed tomography in the preoperative staging of non-small-cell lung cancer: a comparison study. Ann Intern Med 1997; 127:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/24\">",
"      Fritscher-Ravens A, Bohuslavizki KH, Brandt L, et al. Mediastinal lymph node involvement in potentially resectable lung cancer: comparison of CT, positron emission tomography, and endoscopic ultrasonography with and without fine-needle aspiration. Chest 2003; 123:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/25\">",
"      Larsen SS, Vilmann P, Krasnik M, et al. Endoscopic ultrasound guided biopsy performed routinely in lung cancer staging spares futile thoracotomies: preliminary results from a randomised clinical trial. Lung Cancer 2005; 49:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/26\">",
"      LeBlanc JK, Devereaux BM, Imperiale TF, et al. Endoscopic ultrasound in non-small cell lung cancer and negative mediastinum on computed tomography. Am J Respir Crit Care Med 2005; 171:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/27\">",
"      Eloubeidi MA, Cerfolio RJ, Chen VK, et al. Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg 2005; 79:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/28\">",
"      Wallace MB, Ravenel J, Block MI, et al. Endoscopic ultrasound in lung cancer patients with a normal mediastinum on computed tomography. Ann Thorac Surg 2004; 77:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/29\">",
"      Varadarajulu S, Schmulewitz N, Wildi SM, et al. Accuracy of EUS in staging of T4 lung cancer. Gastrointest Endosc 2004; 59:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/30\">",
"      Giovannini M, Seitz JF, Monges G, et al. Fine-needle aspiration cytology guided by endoscopic ultrasonography: results in 141 patients. Endoscopy 1995; 27:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/31\">",
"      Wiersema MJ, Vazquez-Sequeiros E, Wiersema LM. Evaluation of mediastinal lymphadenopathy with endoscopic US-guided fine-needle aspiration biopsy. Radiology 2001; 219:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/32\">",
"      Wallace MB, Fritscher-Ravens A, Savides TJ. Endoscopic ultrasound for the staging of non-small-cell lung cancer. Endoscopy 2003; 35:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/33\">",
"      Yasuda I, Kato T, Asano F, et al. Mediastinal Lymph Node Staging in Potentially Resectable Non-Small Cell Lung Cancer: A Prospective Comparison of CT and EUS/EUS-FNA. Respiration 2009; 78:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/34\">",
"      Arita T, Kuramitsu T, Kawamura M, et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 1995; 50:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/35\">",
"      Wallace MB, Block MI, Gillanders W, et al. Accurate molecular detection of non-small cell lung cancer metastases in mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. Chest 2005; 127:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/36\">",
"      Pellis&eacute; M, Castells A, Gin&egrave;s A, et al. Detection of lymph node micrometastases by gene promoter hypermethylation in samples obtained by endosonography- guided fine-needle aspiration biopsy. Clin Cancer Res 2004; 10:4444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/37\">",
"      Singh P, Camazine B, Jadhav Y, et al. Endoscopic ultrasound as a first test for diagnosis and staging of lung cancer: a prospective study. Am J Respir Crit Care Med 2007; 175:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/38\">",
"      Ringbaek TJ, Krasnik M, Clementsen P, et al. Transesophageal endoscopic ultrasound/fine-needle aspiration diagnosis of a malignant adrenal gland in a patient with non-small cell lung cancer and a negative CT scan. Lung Cancer 2005; 48:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/39\">",
"      Chang KJ, Erickson RA, Nguyen P. Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration of the left adrenal gland. Gastrointest Endosc 1996; 44:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/40\">",
"      Annema JT, Veseli&ccedil; M, Versteegh MI, et al. Mediastinal restaging: EUS-FNA offers a new perspective. Lung Cancer 2003; 42:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/41\">",
"      DeWitt J, LeBlanc J, McHenry L, et al. Endoscopic ultrasound-guided fine needle aspiration cytology of solid liver lesions: a large single-center experience. Am J Gastroenterol 2003; 98:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/42\">",
"      tenBerge J, Hoffman BJ, Hawes RH, et al. EUS-guided fine needle aspiration of the liver: indications, yield, and safety based on an international survey of 167 cases. Gastrointest Endosc 2002; 55:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/43\">",
"      Muehlstaedt M, Bruening R, Diebold J, et al. CT/fluoroscopy-guided transthoracic needle biopsy: sensitivity and complication rate in 98 procedures. J Comput Assist Tomogr 2002; 26:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/44\">",
"      Wiersema MJ, Vilmann P, Giovannini M, et al. Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. Gastroenterology 1997; 112:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/45\">",
"      Wildi SM, Hoda RS, Fickling W, et al. Diagnosis of benign cysts of the mediastinum: the role and risks of EUS and FNA. Gastrointest Endosc 2003; 58:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/46\">",
"      Annema JT, Veseli&ccedil; M, Versteegh MI, Rabe KF. Mediastinitis caused by EUS-FNA of a bronchogenic cyst. Endoscopy 2003; 35:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/47\">",
"      Ryan AG, Zamvar V, Roberts SA. Iatrogenic candidal infection of a mediastinal foregut cyst following endoscopic ultrasound-guided fine-needle aspiration. Endoscopy 2002; 34:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12552/abstract/48\">",
"      von Bartheld MB, van Kralingen KW, Veenendaal RA, et al. Mediastinal-esophageal fistulae after EUS-FNA of tuberculosis of the mediastinum. Gastrointest Endosc 2010; 71:210.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4395 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-1FFB8D27E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12552=[""].join("\n");
var outline_f12_16_12552=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fine needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Benign diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Malignant diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      STAGING NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Primary tumor (T)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lymph nodes (N)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - No lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Molecular analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Metastasis (M)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Restaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ADVANTAGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DISADVANTAGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4395\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4395|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/34/27183\" title=\"diagnostic image 1\">",
"      CT versus EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/31/27135\" title=\"diagnostic image 2\">",
"      EUS lymph node FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/59/18356\" title=\"diagnostic image 3\">",
"      EUS FNA small cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/60/35778\" title=\"diagnostic image 4\">",
"      EUS liver metastasis FNA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4395|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/10/167\" title=\"figure 1\">",
"      Mediastinal LN approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/28/19914\" title=\"figure 2\">",
"      IASLC lymph node map",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4395|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/35/16951\" title=\"picture 1\">",
"      EUS FNA sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4395|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/43/20157\" title=\"table 2\">",
"      Lung cancer TMN staging 6th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/4/13388\" title=\"table 3\">",
"      Changes 7th ed TNM lung ca",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=related_link\">",
"      Diagnosis and staging of non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=related_link\">",
"      Endobronchial ultrasound: Indications, advantages, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43427?source=related_link\">",
"      Endobronchial ultrasound: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=related_link\">",
"      Management of stage III non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=related_link\">",
"      Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_16_12553="Epiglottitis (supraglottitis): Treatment and prevention";
var content_f12_16_12553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epiglottitis (supraglottitis): Treatment and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/16/12553/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/16/12553/contributors\">",
"     Charles R Woods, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/16/12553/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/16/12553/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/16/12553/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/16/12553/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/16/12553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/16/12553/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/16/12553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epiglottitis is inflammation of the epiglottis and adjacent supraglottic structures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/1\">",
"     1",
"    </a>",
"    ]. Without treatment, epiglottitis can progress to life-threatening airway obstruction. A rapid overview of the recognition and management is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef80169 \" href=\"UTD.htm?25/10/25773\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The treatment and prevention of epiglottitis will be reviewed here. The pathogenesis, etiology, and clinical features are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two key aspects to the treatment of acute epiglottitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance of the airway",
"     </li>",
"     <li>",
"      Administration of appropriate antimicrobial agents (it may be reasonable to withhold antibiotics in rare patients in whom the epiglottic edema is clearly known to be caused by inhalational, chemical, or thermal injury)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients in whom epiglottitis is suspected should be monitored continuously by clinicians who are able to perform rapid resuscitation in a setting that has the equipment needed for airway stabilization and ventilation (eg, the emergency department, operating room, or intensive care unit). Humidified supplemental oxygen should be administered as indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/2\">",
"     2",
"    </a>",
"    ]. A rapid overview of the recognition and management of epiglottitis is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef80169 \" href=\"UTD.htm?25/10/25773\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Interactions with children who have signs of severe respiratory distress (eg, anxiety, \"sniffing\" (",
"    <a class=\"graphic graphic_picture graphicRef76538 \" href=\"UTD.htm?8/0/8197\">",
"     picture 1",
"    </a>",
"    ) or \"tripod\" posture (",
"    <a class=\"graphic graphic_picture graphicRef79826 \" href=\"UTD.htm?25/54/26465\">",
"     picture 2",
"    </a>",
"    )) should be conducted in a manner that minimizes apprehension. Unnecessary physical examination and diagnostic testing should be omitted until after the airway is secure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link&amp;anchor=H16#H16\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\", section on 'Examining children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epiglottitis protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coordinated multidisciplinary care, when available, is optimal in the management of patients with signs of severe upper airway obstruction, including those with epiglottitis; securing the airway is of utmost importance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the pre-Hib vaccine era, many medical centers established protocols for the diagnosis and management of patients with suspected epiglottitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The protocols defined roles and responsibilities for various specialists (eg, emergency medicine clinicians, anesthesiologists, otolaryngologists, critical care intensivists, radiologists,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infectious disease specialists). Such protocols were designed to ensure rapid airway control and initiation of antimicrobial therapy. The use of such protocols was associated with lower morbidity and mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/5\">",
"     5",
"    </a>",
"    ]. Epiglottitis protocols generally are no longer needed in areas with sustained high Hib-vaccination rates. However, these may need to be reestablished in areas of developed countries that experience any resurgence of Hib cases associated with increased prevalence of unvaccinated children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     AIRWAY MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of the airway is the mainstay of treatment of epiglottitis. Initial airway management is based upon the degree of respiratory distress and the likelihood of epiglottitis, as determined by clinical assessment (",
"    <a class=\"graphic graphic_table graphicRef80169 \" href=\"UTD.htm?25/10/25773\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/6\">",
"     6",
"    </a>",
"    ]. In patients with signs of total or near-total airway obstruction, airway control precedes diagnostic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Severe distress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected epiglottitis and signs of severe upper airway obstruction should be transported to the operating room, if time allows, where an artificial airway can be established surgically if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. A physician skilled at airway management should monitor the patient at all times. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link&amp;anchor=H22#H22\">",
"     \"The difficult pediatric airway\", section on 'Surgical airway'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnostic tests (eg, phlebotomy, laryngeal examination, epiglottal cultures), which may provoke anxiety, should be postponed until the airway is secure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link&amp;anchor=H28#H28\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the small diameter of the airway in the young child and the risk for rapid progression to complete obstruction, most experts agree that young children with epiglottitis require placement of an artificial airway, even if they do not present with severe respiratory distress [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This strategy of routine placement of an artificial airway is supported by a systematic review of 749 cases of epiglottitis in children in which mortality was increased among those who were managed without an artificial airway (6 versus &lt;1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prompt establishment of an artificial airway was the standard practice in the United States in the pre-conjugate Haemophilus influenzae type b (Hib) vaccine era. However, as the incidence of Hib epiglottitis declines and the median age of children with acute epiglottitis increases, there is some evidence that carefully selected children with epiglottitis can be managed without intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/10\">",
"     10",
"    </a>",
"    ]. Observational data suggest that epiglottitis that is caused by organisms other than Hib may be associated with a lower risk of airway obstruction than epiglottitis caused by Hib [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link&amp;anchor=H21#H21\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\", section on 'Hib versus non-Hib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Successful management of a subset of children with epiglottitis with close observation in an intensive care unit setting without placement of an artificial airway has been described in a number of case series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/3,7,10-12\">",
"     3,7,10-12",
"    </a>",
"    ]. The proportion of children managed initially without an artificial airway ranged from 4 to 49 percent. Decisions regarding airway management were based upon clinical appearance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    visualization of the supraglottis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. In one series, children managed without artificial airways were older than those who were intubated (mean age 6.1 versus 3.4 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/10\">",
"     10",
"    </a>",
"    ]. In others, management without artificial airway was not related to age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/12\">",
"     12",
"    </a>",
"    ]. Among children initially managed without an artificial airway, 10 to 20 percent eventually required placement of an artificial airway [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is difficult to determine a strict age cutoff as a criterion for placement of an artificial airway in children with epiglottitis. In general, the younger the child is below six years of age, the more prudent it seems to place an artificial airway at the time of presentation and diagnosis. The size of the child (small or large for age), presence of obesity, or presence of any underlying cardiac, pulmonary, or metabolic conditions that would make it difficult to quickly and safely place an airway in the event of clinical deterioration should be considered in the decision to immediately intubate versus observe with noninvasive respiratory support measures discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway management in adult patients with epiglottitis is controversial. Some authors suggest that an artificial airway be established in all adults with epiglottitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/13\">",
"     13",
"    </a>",
"    ], whereas others suggest a more selective approach based upon the results of laryngoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/2,7,14-16\">",
"     2,7,14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend that adult patients with epiglottitis and severe respiratory distress (eg, stridor, drooling, sitting erect, cyanosis) or &gt;50 percent obstruction of the laryngeal lumen undergo placement of an artificial airway [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/7,17\">",
"     7,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that adults with epiglottitis without severe respiratory distress and with &lt;50 percent obstruction of the laryngeal lumen be monitored closely in an intensive care unit setting without placement of an artificial airway [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/2,7,17\">",
"     2,7,17",
"    </a>",
"    ]. In retrospective case series of adults with epiglottitis, the proportion of patients successfully managed without placement of an artificial airway ranges from 70 to 91 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/15-21\">",
"     15-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are managed without placement of an artificial airway may develop delayed acute respiratory compromise, necessitating emergent airway intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/2,3,7,17,22\">",
"     2,3,7,17,22",
"    </a>",
"    ]. In large case series, 3 to 8 percent of patients managed initially without airway placement eventually required airway intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/3,7,17\">",
"     3,7,17",
"    </a>",
"    ]. Such patients must be monitored in an intensive care setting, where the airway can be secured emergently if necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental humidified oxygen may be administered (as tolerated without increasing anxiety) to patients until the airway is secured [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Artificial airway",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether all patients with suspected epiglottitis should have prompt placement of an artificial airway is controversial. Proponents of prompt placement of an artificial airway stress the lack of reliable criteria for distinguishing patients who will develop sudden airway obstruction from those who will have a benign course and the increased",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    associated with emergent establishment of an artificial airway compared with airway placement in a more controlled setting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/5,16,24,25\">",
"     5,16,24,25",
"    </a>",
"    ]. This is particularly true in young children, who have a smaller airway diameter than older children and adults.",
"   </p>",
"   <p>",
"    Proponents of a more selective approach, particularly for adult patients, highlight the observational data suggesting that the majority of adults with epiglottitis can be successfully managed without placement of an artificial airway and the potential adverse effects of intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/3,7,17,26\">",
"     3,7,17,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for placement of an artificial airway in patients with epiglottitis include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/2,7,17,27-29\">",
"     2,7,17,27-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Young age, particularly those &lt;4 to 6 years old (especially if comorbidities are present that may make it difficult to quickly and safely place an airway in the event of clinical deterioration) (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Children'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Severe respiratory distress (eg, \"sniffing\" (",
"      <a class=\"graphic graphic_picture graphicRef76538 \" href=\"UTD.htm?8/0/8197\">",
"       picture 1",
"      </a>",
"      ) or \"tripod\" posture (",
"      <a class=\"graphic graphic_picture graphicRef79826 \" href=\"UTD.htm?25/54/26465\">",
"       picture 2",
"      </a>",
"      ), stridor, drooling, cyanosis)",
"     </li>",
"     <li>",
"      Epiglottic abscess",
"     </li>",
"     <li>",
"      Rapid onset and progression of symptoms",
"     </li>",
"     <li>",
"      &gt;50 percent obstruction of laryngeal lumen",
"     </li>",
"     <li>",
"      Comorbid diabetes or immune deficiency (primarily in adult patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Type of airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of airway that is established depends upon the clinical situation and the expertise of the clinician(s) performing the procedure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endotracheal intubation &ndash; If it can be successfully performed, endotracheal intubation (nasotracheal or orotracheal) is preferred to tracheostomy. Endotracheal intubation is associated with shorter duration of intubation and shorter hospital stay [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/5,7,30\">",
"       5,7,30",
"      </a>",
"      ]. If it can be performed, nasotracheal intubation is preferred to orotracheal intubation because it is easier to keep the endotracheal tube in place [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/31\">",
"       31",
"      </a>",
"      ]. Long-term complications of nasotracheal intubation are rare [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/5,32\">",
"       5,32",
"      </a>",
"      ]",
"      <br/>",
"      <br/>",
"      A nasotracheal tube with a diameter that is 0.5 to 1.0 mm smaller than would otherwise be used in the patient is suggested, when feasible, to reduce the risk of post-intubation sequelae [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link&amp;anchor=H10#H10\">",
"       \"Emergent endotracheal intubation in children\", section on 'Endotracheal tube'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Epiglottic edema is on the lingual surface of the epiglottis. Thus, if orotracheal intubation is performed, the larynx should be exposed with the blade in beneath the epiglottis (ie, with a straight [eg, Miller] blade) rather than in the vallecula (ie, with a curved [eg, MacIntosh] blade). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link&amp;anchor=H11#H11\">",
"       \"Emergent endotracheal intubation in children\", section on 'Laryngoscope handle and blade'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tracheostomy &ndash; Tracheostomy is reserved for patients in whom endotracheal intubation is unsuccessful [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/35\">",
"       35",
"      </a>",
"      ]. In case series, the proportion of patients requiring tracheostomy ranges from 0 to approximately 5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/11,16,19,20,35,36\">",
"       11,16,19,20,35,36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link&amp;anchor=H22#H22\">",
"       \"The difficult pediatric airway\", section on 'Surgical airway'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cricothyroidotomy &ndash; Surgical cricothyroidotomy (cricothyrotomy) may be necessary if neither endotracheal intubation nor tracheostomy can be performed. Bag-mask valve ventilation may be attempted while preparation is made to perform a cricothyroidotomy. If oxygenation cannot be maintained, however, cricothyroidotomy is required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"       \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link&amp;anchor=H18#H18\">",
"       \"The difficult pediatric airway\", section on 'Laryngeal mask airway'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"       \"The difficult airway in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Post-intubation care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-intubation care is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link&amp;anchor=H25#H25\">",
"     \"Emergent endotracheal intubation in children\", section on 'Post-intubation care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are intubated during treatment for epiglottitis require meticulous respiratory nursing care and suctioning. Inadvertent extubation must be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Extubation criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intubation for two to three days is usually necessary before extubation can be safely accomplished [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/8\">",
"     8",
"    </a>",
"    ]. Criteria for extubation include resolution of",
"    <span class=\"nowrap\">",
"     epiglottal/supraglottal",
"    </span>",
"    swelling as indicated by laryngoscopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an air leak around the artificial airway, resolution of fever, and ability to swallow comfortably [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/8,10,35,37\">",
"     8,10,35,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of glucocorticoids in airway management of patients with epiglottitis is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/38\">",
"     38",
"    </a>",
"    ]. The primary rationale for the use of glucocorticoids is the potential reduction in airway inflammation with associated improvement of airway patency.",
"   </p>",
"   <p>",
"    We suggest that glucocorticoids not be used in the initial treatment of epiglottitis. However, they may be beneficial in selected patients for whom extubation has proved difficult after several days of appropriate antimicrobial therapy.",
"   </p>",
"   <p>",
"    The use of glucocorticoids in patients with epiglottitis is described in case series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/7,19,20,36,39-42\">",
"     7,19,20,36,39-42",
"    </a>",
"    ]. The proportion of patients treated with glucocorticoids ranges from 20 to 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/15,27,38\">",
"     15,27,38",
"    </a>",
"    ]. However, direct evidence of a benefit from glucocorticoids for patients with epiglottitis is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/5,43\">",
"     5,43",
"    </a>",
"    ]. In retrospective studies, glucocorticoid therapy has not been associated with reduced length of stay, duration of intubation, or duration of stay in the intensive care unit, perhaps because glucocorticoids were administered selectively to sicker patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little published information regarding adverse effects of glucocorticoids in epiglottitis. Gastrointestinal bleeding requiring blood transfusion has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/23,44\">",
"     23,44",
"    </a>",
"    ]. Another concern is potential risk of progressive viral infection or secondary bacterial infection, but these have not been reported. Glucocorticoids may exacerbate varicella and should be avoided in patients with varicella or who have been exposed to varicella and remain in the incubation period [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23110?source=see_link\">",
"     \"Treatment of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authors advocate administration of bronchodilators, such as racemic epinephrine, pending definitive airway intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/2\">",
"     2",
"    </a>",
"    ]. However, others suggest that this intervention is without benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/5,37\">",
"     5,37",
"    </a>",
"    ]. We suggest not using bronchodilators in the management of patients with epiglottitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to airway management, patients with epiglottitis require antimicrobial therapy. Empiric antimicrobial therapy for patients with epiglottitis is directed toward the most likely organisms in a given patient (",
"    <a class=\"graphic graphic_table graphicRef54481 \" href=\"UTD.htm?7/29/7644\">",
"     table 2",
"    </a>",
"    ). Once culture and susceptibility results are available, the regimen should be adjusted to provide optimal coverage of the organism isolated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link&amp;anchor=H6#H6\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\", section on 'Infectious causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epiglottitis is a life-threatening infection. Empiric therapy should be initiated before the results of cultures are available. The empiric regimen generally should provide coverage against the following pathogens:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Haemophilus influenzae type b",
"     </li>",
"     <li>",
"      Penicillin-resistant Streptococcus pneumoniae",
"     </li>",
"     <li>",
"      Beta-hemolytic streptococci",
"     </li>",
"     <li>",
"      Staphylococcus aureus, including community-acquired methicillin-resistant S. aureus (MRSA) strains",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link&amp;anchor=H6#H6\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\", section on 'Infectious causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of agents depends upon on local antibiotic resistance patterns and the clinical status of the patient. We suggest combination therapy with a third-generation cephalosporin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ) AND an antistaphylococcal agent active against MRSA (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef60306 \" href=\"UTD.htm?30/35/31292\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/47\">",
"     47",
"    </a>",
"    ]. Use of an antistaphylococcal penicillin or first-generation cephalosporin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ) can be considered as part of combination therapy if MRSA is NOT an etiologic concern. Similarly, single-agent therapy (eg, ceftriaxone, cefotaxime,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    ) is an option if MRSA is NOT an etiologic concern [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    as the antistaphylococcal agent in the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those with concomitant moderate to severe sepsis.",
"     </li>",
"     <li>",
"      Those who may have concomitant meningitis (such patients should also receive a third- or fourth-generation cephalosporin for coverage of gram-negative organisms). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"       \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=see_link\">",
"       \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'Empiric therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Those from areas with an increased prevalence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      -resistant MRSA isolates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the patient history suggests potential for severe hypersensitivity reaction to beta-lactam antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    plus a quinolone antibiotic may be a reasonable option. Consultation with an expert in pediatric infectious disease may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Specific therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an organism is identified by culture of the epiglottis or blood, the antimicrobial regimen should be adjusted according to susceptibility testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of antibiotics for the treatment of epiglottitis is unknown. Most clinicians treat for 7 to 10 days depending upon patient response [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/5,37\">",
"     5,37",
"    </a>",
"    ]. A longer course may be necessary in patients with bacteremia, meningitis, or immunodeficiency.",
"   </p>",
"   <p>",
"    A portion of the course may be administered orally if the patient is clinically improved and an appropriate oral antibiotic is available [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with epiglottitis should be monitored in an intensive care unit (whether or not an artificial airway has been placed). Daily examination of the supraglottis is necessary to assess the response to therapy, look for complications (eg, epiglottic abscess), and monitor for delayed airway obstruction (in patients managed without an artificial airway) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/3,17,38\">",
"     3,17,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epiglottal swelling is generally improved after two to three days of antimicrobial therapy. Persistence of epiglottal swelling may be caused by inadequate treatment or development of an epiglottic abscess.",
"   </p>",
"   <p>",
"    Persistent fever may be related to development of secondary focus of infection (eg, pneumonia), nosocomial infection, or a reaction to antimicrobial therapy (ie, drug fever, a diagnosis of exclusion). Patients should be examined for extra-epiglottic manifestations (eg, pneumonia), particularly if a pathogen that frequently causes invasive disease at other sites (eg, S. pneumoniae, Hib) is isolated. Additional evaluation for extra-epiglottic manifestations is guided by clinical findings. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ADDITIONAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of an immune deficiency should be considered in children who develop Haemophilus influenzae type b (Hib) epiglottitis or pneumococcal epiglottitis with a serotype contained in the pneumococcal vaccine despite having received at least three doses of the respective conjugate vaccines. In such children, we suggest that quantitative immunoglobulins and complement activity be obtained and that the peripheral blood smear be examined for Howell-Jolly bodies (",
"    <a class=\"graphic graphic_picture graphicRef60588 \" href=\"UTD.htm?38/45/39638\">",
"     picture 3",
"    </a>",
"    ). The presence of Howell-Jolly bodies most frequently indicates either absence of the spleen (eg, surgical removal) or splenic hypofunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic explanations other than classical immunodeficiency conditions also may account for Hib vaccine failure. Single nucleotide polymorphisms (SNP) associated with increased risk of Hib disease in vaccinated children recently have been identified among 172 white children with Hib vaccine failure diagnosed October 1992 through December 2005 in the UK [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/50\">",
"     50",
"    </a>",
"    ]. Six of 9 children homozygous for recessive alleles in the rs1554286 SNP in the promoter region of the interleukin 10 gene developed epiglottitis. This represented a 5.8-fold increased risk for epiglottitis over other children in this vaccine failure cohort who were heterozygous or homozygous for dominant alleles at this site (95% CI: 2.4-14.2, P&lt;.0001). Another SNP also was found to be associated with nonmeningitis, nonepiglottitis Hib disease in this cohort. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with acute epiglottitis recover without residual airway or other problems if the airway is promptly secured and appropriate antimicrobial therapy is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who require tracheostomy may have tracheostomy-related complications (eg, wound problem, tracheocutaneous fistula) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injury related to hypoxemia that occurs before airway intervention or that result from progression of associated sepsis after institution of therapy is not always reversible. Most deaths are the result of cardiorespiratory arrest (secondary to airway obstruction)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delays in presentation for care or in securing the airway [",
"    <a class=\"abstract\" href=\"UTD.htm?12/16/12553/abstract/10\">",
"     10",
"    </a>",
"    ]. Death also may result as a complication of hypoxemia or sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of Hib infections through infant immunization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemoprophylaxis of contacts is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=see_link\">",
"     \"Prevention of Haemophilus influenzae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevention of S. pneumonia infections through immunization is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Rapid overview",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epiglottitis (supraglottitis) is inflammation of the epiglottis and adjacent supraglottic structures. A rapid overview of the recognition and management of epiglottitis is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef80169 \" href=\"UTD.htm?25/10/25773\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of acute epiglottitis centers on maintenance of the airway and administration of appropriate antimicrobial agents. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Airway",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial airway management is based upon the degree of respiratory distress and the likelihood of epiglottitis, as determined by clinical assessment. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with epiglottitis and severe respiratory distress (eg, \"sniffing\" (",
"      <a class=\"graphic graphic_picture graphicRef76538 \" href=\"UTD.htm?8/0/8197\">",
"       picture 1",
"      </a>",
"      ) or \"tripod\" posture (",
"      <a class=\"graphic graphic_picture graphicRef79826 \" href=\"UTD.htm?25/54/26465\">",
"       picture 2",
"      </a>",
"      ), stridor, drooling, cyanosis) should undergo prompt placement of an artificial airway. In those with impending or complete obstruction, endotracheal intubation should be performed immediately in the emergency department.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that most children younger than six years of age with epiglottitis undergo prompt placement of an artificial airway, even in the absence of severe respiratory distress (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that adults with epiglottitis without severe respiratory distress and with &lt;50 percent obstruction of the laryngeal lumen be monitored closely in an intensive care unit setting without immediate placement of an artificial airway (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Additional indications for urgent placement of an artificial airway may include epiglottic abscess, comorbid diabetes mellitus (in adults), and immune deficiency. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The type of airway that is established depends upon the clinical situation and the expertise of the clinician(s) performing the procedure. Oro- or nasotracheal intubation is preferred as the first measures. Surgical airways are reserved for patients in whom endotracheal intubation is unsuccessful. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Type of airway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Criteria for extubation include resolution of",
"      <span class=\"nowrap\">",
"       epiglottal/supraglottal",
"      </span>",
"      swelling as indicated by laryngoscopy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an air leak around the endotracheal tube, resolution of fever, and ability to swallow comfortably. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Extubation criteria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Antimicrobials",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The empiric antimicrobial regimen depends upon the most likely organisms in a given patient (",
"      <a class=\"graphic graphic_table graphicRef54481 \" href=\"UTD.htm?7/29/7644\">",
"       table 2",
"      </a>",
"      ), local antibiotic resistance patterns, and the clinical status of the patient. Once culture and susceptibility results are available, the regimen should be adjusted to provide optimal coverage of the organism isolated. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest combination therapy with a third-generation cephalosporin (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ) AND an antistaphylococcal agent active against MRSA (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef60306 \" href=\"UTD.htm?30/35/31292\">",
"       table 3",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of antibiotics for the treatment of epiglottitis is unknown. Most clinicians treat for 7 to 10 days depending upon patient response. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment response",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with epiglottitis should be monitored in an intensive care unit (whether or not an artificial airway has been placed). Daily examination of the supraglottis is necessary to assess the response to therapy, look for complications (eg, epiglottic abscess), and monitor for delayed airway obstruction (in patients managed without an artificial airway).",
"     </li>",
"     <li>",
"      Epiglottal swelling is generally improved after two to three days of antimicrobial therapy. Persistence of epiglottal swelling may be caused by inadequate treatment or development of an epiglottic abscess. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with acute epiglottis recover without residual airway or other problems if the airway is promptly secured and appropriate antimicrobial therapy is administered. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/1\">",
"      Rafei K, Lichenstein R. Airway infectious disease emergencies. Pediatr Clin North Am 2006; 53:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/2\">",
"      Sobol SE, Zapata S. Epiglottitis and croup. Otolaryngol Clin North Am 2008; 41:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/3\">",
"      Andreassen UK, Baer S, Nielsen TG, et al. Acute epiglottitis--25 years experience with nasotracheal intubation, current management policy and future trends. J Laryngol Otol 1992; 106:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/4\">",
"      Andreassen UK, Husum B, Tos M, Leth N. Acute epiglottitis in adults. A management protocol based on a 17-year material. Acta Anaesthesiol Scand 1984; 28:155.",
"     </a>",
"    </li>",
"    <li>",
"     Cherry JD. Epiglottitis (supraglottitis). In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL.  (Eds), Saunders, Philadelphia 2009. p.244.",
"    </li>",
"    <li>",
"     Fleisher GR. Infectious disease emergencies. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.783.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/7\">",
"      Mayo-Smith MF, Spinale JW, Donskey CJ, et al. Acute epiglottitis. An 18-year experience in Rhode Island. Chest 1995; 108:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/8\">",
"      Stroud RH, Friedman NR. An update on inflammatory disorders of the pediatric airway: epiglottitis, croup, and tracheitis. Am J Otolaryngol 2001; 22:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/9\">",
"      Cantrell RW, Bell RA, Morioka WT. Acute epiglottitis: intubation versus tracheostomy. Laryngoscope 1978; 88:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/10\">",
"      Damm M, Eckel HE, Jungeh&uuml;lsing M, Roth B. Airway endoscopy in the interdisciplinary management of acute epiglottitis. Int J Pediatr Otorhinolaryngol 1996; 38:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/11\">",
"      McEwan J, Giridharan W, Clarke RW, Shears P. Paediatric acute epiglottitis: not a disappearing entity. Int J Pediatr Otorhinolaryngol 2003; 67:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/12\">",
"      Trollfors B, Nyl&eacute;n O, Strangert K. Acute epiglottitis in children and adults in Sweden 1981-3. Arch Dis Child 1990; 65:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/13\">",
"      Ames WA, Ward VM, Tranter RM, Street M. Adult epiglottitis: an under-recognized, life-threatening condition. Br J Anaesth 2000; 85:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/14\">",
"      Wolf M, Strauss B, Kronenberg J, Leventon G. Conservative management of adult epiglottitis. Laryngoscope 1990; 100:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/15\">",
"      H&eacute;bert PC, Ducic Y, Boisvert D, Lamothe A. Adult epiglottitis in a Canadian setting. Laryngoscope 1998; 108:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/16\">",
"      Ng HL, Sin LM, Li MF, et al. Acute epiglottitis in adults: a retrospective review of 106 patients in Hong Kong. Emerg Med J 2008; 25:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/17\">",
"      Berger G, Landau T, Berger S, et al. The rising incidence of adult acute epiglottitis and epiglottic abscess. Am J Otolaryngol 2003; 24:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/18\">",
"      Chang YL, Lo SH, Wang PC, Shu YH. Adult acute epiglottitis: experiences in a Taiwanese setting. Otolaryngol Head Neck Surg 2005; 132:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/19\">",
"      Guldfred LA, Lyhne D, Becker BC. Acute epiglottitis: epidemiology, clinical presentation, management and outcome. J Laryngol Otol 2008; 122:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/20\">",
"      Frantz TD, Rasgon BM, Quesenberry CP Jr. Acute epiglottitis in adults. Analysis of 129 cases. JAMA 1994; 272:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/21\">",
"      Dort JC, Frohlich AM, Tate RB. Acute epiglottitis in adults: diagnosis and treatment in 43 patients. J Otolaryngol 1994; 23:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/22\">",
"      Gerrish SP, Jones AS, Watson DM, Wight RG. Adult epiglottitis. Br Med J (Clin Res Ed) 1987; 295:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/23\">",
"      DiTirro FR, Silver MH, Hengerer AS. Acute epiglottitis: evolution of management in the community hospital. Int J Pediatr Otorhinolaryngol 1984; 7:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/24\">",
"      Bass JW, Steele RW, Wiebe RA. Acute epiglottitis. A surgical emergency. JAMA 1974; 229:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/25\">",
"      Margolis CZ, Ingram DL, Meyer JH. Routine tracheotomy in Hemophilus influenzae type b epiglottitis. J Pediatr 1972; 81:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/26\">",
"      Shah RK, Stocks C. Epiglottitis in the United States: national trends, variances, prognosis, and management. Laryngoscope 2010; 120:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/27\">",
"      Katori H, Tsukuda M. Acute epiglottitis: analysis of factors associated with airway intervention. J Laryngol Otol 2005; 119:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/28\">",
"      Solomon P, Weisbrod M, Irish JC, Gullane PJ. Adult epiglottitis: the Toronto Hospital experience. J Otolaryngol 1998; 27:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/29\">",
"      Deeb ZE, Yenson AC, DeFries HO. Acute epiglottitis in the adult. Laryngoscope 1985; 95:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/30\">",
"      Milko DA, Marshak G, Striker TW. Nasotracheal intubation in the treatment of acute epiglottitis. Pediatrics 1974; 53:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/31\">",
"      Schloss MD, Hannallah R, Baxter JD. Acute epiglottitis: 26 years' experience at the Montreal Children's Hospital. J Otolaryngol 1979; 8:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/32\">",
"      Schuller DE, Birck HG. The safety of intubation in croup and epiglottitis: an eight-year follow-up. Laryngoscope 1975; 85:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/33\">",
"      Heldtander P, Lee P. Treatment of acute epiglottitis in children by long-term intubation. Acta Otolaryngol 1973; 75:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/34\">",
"      Allen TH, Steven IM. Prolonged nasotracheal intubation in infants and children. Br J Anaesth 1972; 44:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/35\">",
"      Battaglia JD, Lockhart CH. Management of acute epiglottitis by nasotracheal intubation. Am J Dis Child 1975; 129:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/36\">",
"      Nakamura H, Tanaka H, Matsuda A, et al. Acute epiglottitis: a review of 80 patients. J Laryngol Otol 2001; 115:31.",
"     </a>",
"    </li>",
"    <li>",
"     Asher MI. Infections of the upper respiratory tract. In: Pediatric Respiratory Medicine, Taussig LM, Landau LI.  (Eds), Mosby, St. Louis 1999. p.540.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/38\">",
"      Glynn F, Fenton JE. Diagnosis and management of supraglottitis (epiglottitis). Curr Infect Dis Rep 2008; 10:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/39\">",
"      Torkkeli T, Ruoppi P, Nuutinen J, Kari A. Changed clinical course and current treatment of acute epiglottitis in adults a 12-year experience. Laryngoscope 1994; 104:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/40\">",
"      Hafidh MA, Sheahan P, Keogh I, Walsh RM. Acute epiglottitis in adults: a recent experience with 10 cases. J Laryngol Otol 2006; 120:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/41\">",
"      Glicklich M, Cohen RD, Jona JZ. Steroids and bag and mask ventilation in the treatment of acute epiglottitis. J Pediatr Surg 1979; 14:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/42\">",
"      Strome M, Jaffe B. Epiglottitis--individualized management with steroids. Laryngoscope 1974; 84:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/43\">",
"      Baxter FJ, Dunn GL. Acute epiglottitis in adults. Can J Anaesth 1988; 35:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/44\">",
"      Kyrcz RW, Indyk D. Atypical acute epiglottitis with gastrointestinal bleeding. J Fam Pract 1988; 27:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/45\">",
"      Kaditis AG, Wald ER. Viral croup: current diagnosis and treatment. Pediatr Infect Dis J 1998; 17:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/46\">",
"      Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics 1993; 92:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/47\">",
"      Ward MA. Emergency department management of acute respiratory infections. Semin Respir Infect 2002; 17:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/48\">",
"      Shah RK, Roberson DW, Jones DT. Epiglottitis in the Hemophilus influenzae type B vaccine era: changing trends. Laryngoscope 2004; 114:557.",
"     </a>",
"    </li>",
"    <li>",
"     Shah SS, Hopkins PM, Newland JG. Middle respiratory tract infections and bronchiolitis. In: Comprehensive Pediatric Hospital Medicine, Zaoutis LB, Chiang WV.  (Eds), Mosby, Philadelphia 2007. p.369.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/50\">",
"      Ladhani SN, Davila S, Hibberd ML, et al. Association between single-nucleotide polymorphisms in Mal/TIRAP and interleukin-10 genes and susceptibility to invasive haemophilus influenzae serotype b infection in immunized children. Clin Infect Dis 2010; 51:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/16/12553/abstract/51\">",
"      Corbett HJ, Mann KS, Mitra I, et al. Tracheostomy--a 10-year experience from a UK pediatric surgical center. J Pediatr Surg 2007; 42:1251.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6076 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12553=[""].join("\n");
var outline_f12_16_12553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epiglottitis protocols",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AIRWAY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Severe distress",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Artificial airway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Type of airway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Post-intubation care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Extubation criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANTIMICROBIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Specific therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ADDITIONAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Airway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6076\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6076|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/0/8197\" title=\"picture 1\">",
"      Epiglottitis classic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/54/26465\" title=\"picture 2\">",
"      Epiglottitis tripod posture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/45/39638\" title=\"picture 3\">",
"      Howell-Jolly bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6076|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/10/25773\" title=\"table 1\">",
"      Epiglottitis in children &ndash; Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/29/7644\" title=\"table 2\">",
"      Epiglottitis microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/35/31292\" title=\"table 3\">",
"      Epiglottitis Rx regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=related_link\">",
"      Treatment of bacterial meningitis caused by specific pathogens in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23110?source=related_link\">",
"      Treatment of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_16_12554="Diltiazem: Drug information";
var content_f12_16_12554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diltiazem: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/11/6326?source=see_link\">",
"    see \"Diltiazem: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/14/16617?source=see_link\">",
"    see \"Diltiazem: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cardizem&reg;;",
"     </li>",
"     <li>",
"      Cardizem&reg; CD;",
"     </li>",
"     <li>",
"      Cardizem&reg; LA;",
"     </li>",
"     <li>",
"      Cartia XT&reg;;",
"     </li>",
"     <li>",
"      Dilacor XR&reg;;",
"     </li>",
"     <li>",
"      Dilt-CD;",
"     </li>",
"     <li>",
"      Dilt-XR;",
"     </li>",
"     <li>",
"      Diltia XT&reg;;",
"     </li>",
"     <li>",
"      Diltzac;",
"     </li>",
"     <li>",
"      Matzim&reg; LA;",
"     </li>",
"     <li>",
"      Taztia XT&reg;;",
"     </li>",
"     <li>",
"      Tiazac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Diltiaz CD&reg;;",
"     </li>",
"     <li>",
"      Apo-Diltiaz SR&reg;;",
"     </li>",
"     <li>",
"      Apo-Diltiaz TZ&reg;;",
"     </li>",
"     <li>",
"      Apo-Diltiaz&reg;;",
"     </li>",
"     <li>",
"      Apo-Diltiaz&reg; Injectable;",
"     </li>",
"     <li>",
"      Ava-Diltiazem;",
"     </li>",
"     <li>",
"      Cardizem&reg; CD;",
"     </li>",
"     <li>",
"      CO Diltiazem CD;",
"     </li>",
"     <li>",
"      CO Diltiazem T;",
"     </li>",
"     <li>",
"      Diltiazem HCl ER&reg;;",
"     </li>",
"     <li>",
"      Diltiazem Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Diltiazem TZ;",
"     </li>",
"     <li>",
"      Diltiazem-CD;",
"     </li>",
"     <li>",
"      Nu-Diltiaz;",
"     </li>",
"     <li>",
"      Nu-Diltiaz-CD;",
"     </li>",
"     <li>",
"      PMS-Diltiazem CD;",
"     </li>",
"     <li>",
"      ratio-Diltiazem CD;",
"     </li>",
"     <li>",
"      Sandoz-Diltiazem CD;",
"     </li>",
"     <li>",
"      Sandoz-Diltiazem T;",
"     </li>",
"     <li>",
"      Teva-Diltiazem;",
"     </li>",
"     <li>",
"      Teva-Diltiazem CD;",
"     </li>",
"     <li>",
"      Teva-Diltiazem HCL ER Capsules;",
"     </li>",
"     <li>",
"      Tiazac&reg;;",
"     </li>",
"     <li>",
"      Tiazac&reg; XC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F160711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Antiarrhythmic Agent, Class IV;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Nondihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F160662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Angina:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Capsule, extended release:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dilacor XR&reg;, Dilt-XR, Diltia XT&reg;: Initial: 120 mg once daily; titrate over 7-14 days; usual dose range: 120-320 mg/day: maximum: 480 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cardizem&reg; CD, Cartia XT&reg;, Dilt-CD: Initial: 120-180 mg once daily; titrate over 7-14 days; usual dose range: 120-320 mg/day; maximum: 480 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tiazac&reg;, Taztia XT&reg;: Initial: 120-180 mg once daily; titrate over 7-14 days; usual dose range: 120-320 mg/day; maximum: 540 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Tablet, extended release",
"     </i>",
"     (Cardizem&reg; LA, Matzim&reg; LA, Tiazac&reg; XC [CAN; not available in U.S.]): 180 mg once daily; may increase at 7- to 14-day intervals; usual dose range: 120-320 mg/day; maximum: 360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Tablet, immediate release",
"     </i>",
"     (Cardizem&reg;): Usual starting dose: 30 mg 4 times/day; titrate dose gradually at 1- to 2-day intervals; usual dose range: 120-320 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Capsule, extended release (once-daily dosing):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cardizem&reg; CD, Cartia XT&reg;, Dilt-CD: Initial: 180-240 mg once daily; dose adjustment may be made after 14 days; usual dose range (JNC 7): 180-420 mg/day; maximum: 480 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dilacor&reg; XR, Diltia XT&reg;, Dilt-XR: Initial: 180-240 mg once daily; dose adjustment may be made after 14 days; usual dose range (JNC 7): 180-420 mg/day; maximum: 540 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tiazac&reg;, Taztia XT&reg;: Initial: 120-240 mg once daily; dose adjustment may be made after 14 days; usual dose range (JNC 7): 180-420 mg/day; maximum: 540 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Capsule, extended release (twice-daily dosing):",
"     </i>",
"     Initial: 60-120 mg twice daily; dose adjustment may be made after 14 days; usual range: 240-360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Diltiazem is available as a generic intended for either once- or twice-daily dosing, depending on the formulation; verify appropriate extended release capsule formulation is administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Tablet, extended release",
"     </i>",
"     (Cardizem&reg; LA, Matzim&reg; LA, Tiazac&reg; XC [CAN; not available in U.S.]): Initial: 180-240 mg once daily; dose adjustment may be made after 14 days; usual dose range (JNC 7): 120-540 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atrial fibrillation, atrial flutter, PSVT:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial bolus dose:",
"     </i>",
"     0.25 mg/kg actual body weight over 2 minutes (average adult dose: 20 mg); ACLS guideline recommends 15-20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Repeat bolus dose (may be administered after 15 minutes if the response is inadequate):",
"     </i>",
"     0.35 mg/kg actual body weight over 2 minutes (average adult dose: 25 mg); ACLS guideline recommends 20-25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Continuous infusion (infusions &gt;24 hours or infusion rates &gt;15 mg/hour are not recommended):",
"     </i>",
"     Initial infusion rate of 10 mg/hour; rate may be increased in 5 mg/hour increments up to 15 mg/hour as needed; some patients may respond to an initial rate of 5 mg/hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If diltiazem injection is administered by continuous infusion for &gt;24 hours, the possibility of decreased diltiazem clearance, prolonged elimination half-life, and increased diltiazem and/or diltiazem metabolite plasma concentrations should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conversion from I.V. diltiazem to oral diltiazem:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral dose (mg/day) is approximately equal to [rate (mg/hour) x 3 + 3] x 10",
"     </i>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     3 mg/hour = 120 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5 mg/hour = 180 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     7 mg/hour = 240 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     11 mg/hour = 360 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F160686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/14/16617?source=see_link\">",
"      see \"Diltiazem: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Minimal information available; some centers use the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension (unlabeled use):",
"     </b>",
"     Oral: Initial: 1.5-2 mg/kg/day in 3 divided doses (maximum: 6 mg/kg/day, up to 360 mg/day) (Flynn, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F160663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. In the management of hypertension, consider lower initial doses (eg, 120 mg once daily using extended release capsule) and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F160664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution; no dosing adjustments recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dialysis: Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F160665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; no specific dosing recommendations available; extensively metabolized by the liver; half-life is increased in patients with cirrhosis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as hydrochloride [once-daily dosing]: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardizem&reg; CD: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cartia XT&reg;: 120 mg, 180 mg, 240 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilacor XR&reg;: 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilt-CD: 120 mg, 180 mg, 240 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilt-XR: 120 mg, 180 mg, 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diltia XT&reg;: 120 mg, 180 mg, 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diltzac: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Taztia XT&reg;: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tiazac&reg;: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as hydrochloride [twice-daily dosing]: 60 mg, 90 mg, 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as hydrochloride: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 5 mg/mL (5 mL, 10 mL, 25 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 30 mg, 60 mg, 90 mg, 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardizem&reg;: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardizem&reg;: 60 mg, 90 mg, 120 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride [once-daily dosing]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardizem&reg; LA: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Matzim&reg; LA: 180 mg, 240 mg, 300 mg, 360 mg, 420 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F6047983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tiazac&reg; XC: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F160632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet (Cardizem&reg;): Administer before meals and at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Long acting dosage forms: Do not open, chew, or crush; swallow whole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cardizem&reg; CD, Cardizem&reg; LA, Cartia XT&reg;, Dilt-CD, Matzim&reg; LA: May be administered without regards to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dilacor XR&reg;, Dilt-XR, Diltia XT&reg;: Administer on an empty stomach.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Taztia XT&trade;, Tiazac&reg;: Capsules may be opened and sprinkled on a spoonful of applesauce. Applesauce should not be hot and should be swallowed without chewing, followed by drinking a glass of water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tiazac&reg; XC [CAN; not available in U.S.]: Administer at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Bolus doses given over 2 minutes with continuous ECG and blood pressure monitoring. Continuous infusion should be via infusion pump.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     125 mg in 125 mL (total volume) (concentration: 1 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or  NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F160718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Albumin, alcohol (ethyl), amiodarone, amikacin, amphotericin B (conventional), argatroban, aztreonam, bivalirudin, bumetanide, caspofungin, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, cimetidine, ciprofloxacin, clindamycin, dexmedetomidine, digoxin, dobutamine, dopamine, doripenem, doxycycline, epinephrine, erythromycin lactobionate, esmolol, fenoldopam, fentanyl, fluconazole, gentamicin, hetastarch in lactated electrolyte injection (Hextend&reg;), hydromorphone, imipenem/cilastatin, labetalol, lidocaine, lorazepam, meperidine, metoclopramide, metronidazole, midazolam, milrinone, morphine, multivitamins, nesiritide, nicardipine, nitroglycerin, nitroprusside, norepinephrine, oxacillin, pancuronium, penicillin G potassium, pentamidine, piperacillin, potassium chloride, potassium phosphates, ranitidine, sulfamethoxazole/trimethoprim, telavancin, terbutaline, theophylline, ticarcillin/clavulanate potassium, tobramycin, vancomycin, vasopressin, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diazepam, furosemide, micafungin, phenytoin, rifampin, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acetazolamide, acyclovir, aminophylline, ampicillin, ampicillin/sulbactam, heparin, hydrocortisone sodium succinate, insulin (regular), methylprednisolone sodium succinate, metoprolol, nafcillin, procainamide, sodium bicarbonate, tenecteplase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F160631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Essential hypertension; chronic stable angina or angina from coronary artery spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Control of rapid ventricular rate in patients with atrial fibrillation or atrial flutter; conversion of paroxysmal supraventricular tachycardia (PSVT)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F160707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     ACLS guidelines: Injection: Stable narrow-complex tachycardia uncontrolled or unconverted by adenosine or vagal maneuvers or if SVT is recurrent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypertrophic cardiomyopathy; pediatric hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F160720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cardizem&reg; may be confused with Cardene&reg;, Cardene SR&reg;, Cardizem CD&reg;, Cardizem SR&reg;, cortisone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cartia XT&reg; may be confused with Procardia XL&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diltiazem may be confused with Calan&reg;, diazepam, Dilantin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tiazac&reg; may be confused with Tigan&reg;, Tiazac&reg; XC [CAN], Ziac&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cardizem [U.S., Canada, and multiple international markets] may be confused with Cardem brand name for celiprolol [Spain]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cartia XT [U.S.] may be confused with Cartia brand name for aspirin [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dilacor XR [U.S.]  may be confused with Dilacor brand name for verapamil [Brazil]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dipen [Greece] may be confused with Depen brand name for penicillamine [U.S.]; Depin brand name for nifedipine [India]; Depon brand name for acetaminophen [Greece]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tiazac: Brand name for diltiazem [U.S, Canada], but also the brand name for pioglitazone [Chile]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F160709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequencies represent ranges for various dosage forms. Patients with impaired ventricular function and/or conduction abnormalities may have higher incidence of adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (2% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (5% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: AV block (first degree 2% to 8%), edema (lower limb, 2% to 8%), pain (6%), bradycardia (2% to 6%), hypotension (&lt;2% to 4%), vasodilation (2% to 3%), extrasystoles (2%), flushing (1% to 2%), palpitation (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3% to 10%), nervousness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gout (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (1% to 6%), constipation (&lt;2% to 4%), vomiting (2%), diarrhea (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions: Burning, itching (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (1% to 4%), myalgia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (&lt;2% to 10%), pharyngitis (2% to 6%), dyspnea (1% to 6%), bronchitis (1% to 4%), cough (&le;3), sinus congestion (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Alkaline phosphatase increased, allergic reaction, ALT increased, AST increased, amblyopia, amnesia, arrhythmia, AV block (second or third degree), bundle branch block, CHF, depression, dysgeusia, extrapyramidal symptoms, gingival hyperplasia, hemolytic anemia, petechiae, photosensitivity, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, tremor, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F160636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Hypersensitivity to diltiazem or any component of the formulation; sick sinus syndrome (except in patients with a functioning artificial pacemaker); second- or third-degree AV block (except in patients with a functioning artificial pacemaker); severe hypotension (systolic &lt;90 mm Hg); acute MI and pulmonary congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravenous (I.V.): Hypersensitivity to diltiazem or any component of the formulation; sick sinus syndrome (except in patients with a functioning artificial pacemaker); second- or third-degree AV block (except in patients with a functioning artificial pacemaker); severe hypotension (systolic &lt;90 mm Hg); cardiogenic shock; administration concomitantly or within a few hours of the administration of I.V. beta-blockers; atrial fibrillation or flutter associated with accessory bypass tract (eg, Wolff-Parkinson-White syndrome); ventricular tachycardia (with wide-complex tachycardia, must determine whether origin is supraventricular or ventricular)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): I.V. and Oral: Pregnancy; use in women of childbearing potential",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F160617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormalities: May cause first-, second-, and third-degree AV block or sinus bradycardia; risk increases with agents known to slow cardiac conduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Transient dermatologic reactions have been observed with use; if reaction persists, discontinue. May (rarely) progress to erythema multiforme or exfoliative dermatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Rarely, significant elevations in hepatic transaminases have been observed with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: The most common side effect is peripheral edema; occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may require lower starting dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic obstructive cardiomyopathy (HOCM): Use with caution in patients with HOCM; routineuse is currently not recommended due to insufficient evidence (Maron, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Left ventricular dysfunction: Use with caution in left ventricular dysfunction; due to negative inotropic effects, may exacerbate condition. Avoid use of diltiazem in patients with heart failure and reduced ejection fraction (Hunt, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agents with SA/AV nodal-blocking properties: Use caution when using diltiazem together with a beta-blocker; may result in conduction disturbances, hypotension, and worsened LV function. Simultaneous administration of I.V. diltiazem and an I.V. beta-blocker or administration within a few hours of each other may result in asystole and is contraindicated. Use with other agents known to either reduce SA node function and/or AV nodal conduction (eg, digoxin) or reduce sympathetic outflow (eg, clonidine) may increase the risk of serious bradycardia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F160705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F160622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Diltiazem may increase the serum concentration of Alfentanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Anilidopiperidine Opioids may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Diltiazem. Diltiazem may increase the serum concentration of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May increase the serum concentration of Diltiazem. Diltiazem may increase the serum concentration of AtorvaSTATin. Management: Consider using lower atorvastatin doses when used together with diltiazem.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Nondihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine. Management: Consider empiric reductions in carbamazepine dose with initiation of nondihydropyridine calcium channel blockers. Monitor for increased toxic effects of carbamazepine and reduced therapeutic effects of the calcium channel blocker.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloNIDine: May enhance the AV-blocking effect of Calcium Channel Blockers (Nondihydropyridine). Sinus node dysfunction may also be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colestipol: May decrease the absorption of Diltiazem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers (Nondihydropyridine). Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers (Nondihydropyridine). Management: This interaction has only been described with intravenous dantrolene administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Dronedarone. Other electrophysiologic effects of Dronedarone may also be increased. Dronedarone may increase the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Dronedarone.  Management: Use lower starting doses of the nondihydropyridine calcium channel blockers (i.e., verapamil, diltiazem), and only consider increasing calcium channel blocker dose after obtaining ECG-based evidence that the combination is being well-tolerated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Eletriptan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Diltiazem may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Diltiazem may increase the serum concentration of Fosaprepitant. Specifically, diltiazem may increase the concentration of the active metabolite aprepitant. Fosaprepitant may increase the serum concentration of Diltiazem. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Diltiazem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Ivabradine. Ivabradine may enhance the QTc-prolonging effect of Calcium Channel Blockers (Nondihydropyridine). Specifically, the QTc prolonging effects of bepridil may be enhanced. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Ivabradine. Specifically, verapamil or diltiazem may increase serum ivabradine concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Calcium Channel Blockers (Nondihydropyridine) may enhance the neurotoxic effect of Lithium. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Lithium. Decreased or unaltered lithium concentrations have also been reported with this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Diltiazem may increase the serum concentration of Lovastatin. Lovastatin may increase the serum concentration of Diltiazem.  Management: Initiate lovastatin at a maximum adult dose of 10 mg/day, and do not exceed 20 mg/day, in patients receiving diltiazem. Monitor closely for signs of HMG-CoA reductase inhibitor toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade. Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Diltiazem may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Ranolazine.  Management: Limit ranolazine dose to a maximum of 500 mg twice daily when used with diltiazem or verapamil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin (and possibly other related compounds) may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Diltiazem may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Calcium Channel Blockers (Nondihydropyridine) may enhance the anticoagulant effect of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Diltiazem may increase the serum concentration of Simvastatin. Simvastatin may increase the serum concentration of Diltiazem.  Management: Avoid concurrent use of diltiazem with simvastatin when possible.  If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F160653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase risk of hypotension or vasodilation. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Diltiazem serum levels may be elevated if taken with food. Serum concentrations were not altered by grapefruit juice in small clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease diltiazem levels. Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of diltiazem (eg, shepherd&rsquo;s purse). Management: Avoid St John's wort, bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F160639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic and embryotoxic effects have been demonstrated in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F160670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP considers &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F160640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diltiazem is excreted into breastmilk in concentrations similar to those in the maternal plasma.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F160638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 12-hour",
"     </b>",
"     (Diltiazem HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $83.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (100): $94.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $123.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Cardizem CD Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (30): $152.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (30): $192.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (30): $260.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $341.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     360 mg (90): $1494.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Cartia XT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (90): $107.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (90): $130.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (90): $184.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (90): $239.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Dilacor XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (100): $456.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Diltiazem HCl ER Beads Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (90): $93.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (90): $112.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (90): $159.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (90): $207.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     360 mg (90): $211.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     420 mg (90): $221.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Diltiazem HCl ER Coated Beads Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (90): $107.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (90): $130.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (90): $184.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (90): $239.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     360 mg (90): $921.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Diltiazem HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (80): $82.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (80): $96.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (80): $103.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Taztia XT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (30): $34.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (30): $41.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (30): $58.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $76.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     360 mg (30): $77.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Tiazac Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (90): $128.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (90): $154.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (90): $219.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (90): $284.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     360 mg (90): $290.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     420 mg (90): $304.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Diltiazem HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/5 mL (5 mL): $2.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/10 mL (10 mL): $3.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/25 mL (25 mL): $6.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Diltiazem HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $9.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Cardizem LA Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (30): $124.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (30): $131.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (30): $147.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $191.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     360 mg (30): $206.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     420 mg (30): $223.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Matzim LA Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (30): $89.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (30): $100.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $130.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     360 mg (30): $140.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     420 mg (30): $151.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cardizem Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $256.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $298.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (100): $565.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $548.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Diltiazem HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $44.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $72.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (100): $101.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $136.39",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F160626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, blood pressure, ECG, heart rate",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F160641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acalix (AR, PY, VE);",
"     </li>",
"     <li>",
"      Adizem (IE, LU);",
"     </li>",
"     <li>",
"      Adizem-CD (IL);",
"     </li>",
"     <li>",
"      Adizem-XL (IE);",
"     </li>",
"     <li>",
"      Aldizem (HR);",
"     </li>",
"     <li>",
"      Altiazem (BG, HK, IT);",
"     </li>",
"     <li>",
"      Altiazem Retard (IT);",
"     </li>",
"     <li>",
"      Altiazem RR (EE, RU);",
"     </li>",
"     <li>",
"      Angiotrofen (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Angiotrofin (MX);",
"     </li>",
"     <li>",
"      Angiotrofin Retard (MX);",
"     </li>",
"     <li>",
"      Angiozem (PH);",
"     </li>",
"     <li>",
"      Angizem (IT);",
"     </li>",
"     <li>",
"      Apo-diltiazem CD (NZ);",
"     </li>",
"     <li>",
"      Balcor (BR);",
"     </li>",
"     <li>",
"      Beatizem (SG);",
"     </li>",
"     <li>",
"      Bi-Tildiem (FR);",
"     </li>",
"     <li>",
"      Blocalcin (HU);",
"     </li>",
"     <li>",
"      Calcicard (GB);",
"     </li>",
"     <li>",
"      Calnurs (JP);",
"     </li>",
"     <li>",
"      Cardcal (AU);",
"     </li>",
"     <li>",
"      Cardiazem (KP);",
"     </li>",
"     <li>",
"      Cardil (BG, DK, MY, RU);",
"     </li>",
"     <li>",
"      Cardil Retard (GR);",
"     </li>",
"     <li>",
"      Cardium (SG);",
"     </li>",
"     <li>",
"      Cardizem (AU, BR, DK, FI, NO, NZ, SE);",
"     </li>",
"     <li>",
"      Cardizem CD (AU, BR, NZ);",
"     </li>",
"     <li>",
"      Cardizem Retard (DK, FI, SE, TW);",
"     </li>",
"     <li>",
"      Cardizem SR (BR);",
"     </li>",
"     <li>",
"      Cardizem Unotard (TW);",
"     </li>",
"     <li>",
"      Cartia XT (TW);",
"     </li>",
"     <li>",
"      Cascor XL (TH);",
"     </li>",
"     <li>",
"      Coras (AU);",
"     </li>",
"     <li>",
"      Cordila SR (ID);",
"     </li>",
"     <li>",
"      Cordizem (MY);",
"     </li>",
"     <li>",
"      Dasav (MX);",
"     </li>",
"     <li>",
"      Dazil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Deltazen (FR);",
"     </li>",
"     <li>",
"      Diacor LP (FR);",
"     </li>",
"     <li>",
"      Diladel (IT);",
"     </li>",
"     <li>",
"      Dilatam (ZA);",
"     </li>",
"     <li>",
"      Dilatam 120 SR (IL);",
"     </li>",
"     <li>",
"      Dilatam 240 CD (IL);",
"     </li>",
"     <li>",
"      Dilatame (AT);",
"     </li>",
"     <li>",
"      Dilcardia (BF, BJ, CI, ET, GB, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Dilcor (DK);",
"     </li>",
"     <li>",
"      Dilem SR (TH);",
"     </li>",
"     <li>",
"      Dilfar (PT);",
"     </li>",
"     <li>",
"      Dilrene (CZ, FR, HU);",
"     </li>",
"     <li>",
"      Dilta-Hexal (LU);",
"     </li>",
"     <li>",
"      Diltahexal (DE, LU);",
"     </li>",
"     <li>",
"      Diltahexal CD (AU);",
"     </li>",
"     <li>",
"      Diltam (IE);",
"     </li>",
"     <li>",
"      Diltan (BB, BM, BS, BZ, GY, HU, JM, SR, TT);",
"     </li>",
"     <li>",
"      Diltan SR (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Diltelan (KP, TW);",
"     </li>",
"     <li>",
"      Diltelan Depot (IE);",
"     </li>",
"     <li>",
"      Diltiazem-B (HU);",
"     </li>",
"     <li>",
"      Diltiazem-Ethypharm (LU);",
"     </li>",
"     <li>",
"      Diltiazem-Xl (LU);",
"     </li>",
"     <li>",
"      Diltiazyn (CO);",
"     </li>",
"     <li>",
"      Diltime (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Dilzanton (DE);",
"     </li>",
"     <li>",
"      Dilzem (AE, AT, AU, BH, CH, CY, CZ, DE, EG, FI, HR, HU, IE, IN, IQ, IR, JO, KW, LB, LY, NZ, OM, PK, PL, QA, SA, SY, TH, YE);",
"     </li>",
"     <li>",
"      Dilzem CD (AU);",
"     </li>",
"     <li>",
"      Dilzem LA (NZ);",
"     </li>",
"     <li>",
"      Dilzem Retard (AE, AT, BH, CY, CZ, DE, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Dilzem RR (CH);",
"     </li>",
"     <li>",
"      Dilzem SR (GB, NZ);",
"     </li>",
"     <li>",
"      Dilzene (IT);",
"     </li>",
"     <li>",
"      Dilzereal 90 Retard (DE);",
"     </li>",
"     <li>",
"      Dilzicardin (DE);",
"     </li>",
"     <li>",
"      Dinisor (ES);",
"     </li>",
"     <li>",
"      Dinisor Retard (ES);",
"     </li>",
"     <li>",
"      DTM (IN);",
"     </li>",
"     <li>",
"      Entrydil (IE);",
"     </li>",
"     <li>",
"      Ergolan (CL);",
"     </li>",
"     <li>",
"      Gadoserin (JP);",
"     </li>",
"     <li>",
"      Hagen (TW);",
"     </li>",
"     <li>",
"      Helsibon (JP);",
"     </li>",
"     <li>",
"      Herben (KP);",
"     </li>",
"     <li>",
"      Herbesser (JP, MY, TH, TW);",
"     </li>",
"     <li>",
"      Herbesser 180 SR (HK);",
"     </li>",
"     <li>",
"      Herbesser 60 (MY, TH);",
"     </li>",
"     <li>",
"      Herbesser 90 SR (HK, MY, SG, TH);",
"     </li>",
"     <li>",
"      Herbesser R100 (HK, JP);",
"     </li>",
"     <li>",
"      Herbesser R200 (HK, JP);",
"     </li>",
"     <li>",
"      Herbessor (SG);",
"     </li>",
"     <li>",
"      Herbessor 30 (MY);",
"     </li>",
"     <li>",
"      Hesor (TW);",
"     </li>",
"     <li>",
"      Iski (IN);",
"     </li>",
"     <li>",
"      Kaizem CD (IN);",
"     </li>",
"     <li>",
"      Lytelsen (JP);",
"     </li>",
"     <li>",
"      Masdil (ES);",
"     </li>",
"     <li>",
"      Metazem (IE);",
"     </li>",
"     <li>",
"      Mono-Tildiem (LU);",
"     </li>",
"     <li>",
"      Mono-Tildiem SR (SG);",
"     </li>",
"     <li>",
"      Monotildiem (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Myonil (DK);",
"     </li>",
"     <li>",
"      Myonil Retard (DK);",
"     </li>",
"     <li>",
"      Pazeadin (JP);",
"     </li>",
"     <li>",
"      Progor (TH, TW);",
"     </li>",
"     <li>",
"      Surazem (LU);",
"     </li>",
"     <li>",
"      Tazem (TW);",
"     </li>",
"     <li>",
"      Tiadil (PT);",
"     </li>",
"     <li>",
"      Tilazem (AR, CN, CO, EC, MX, PE, UY, ZA);",
"     </li>",
"     <li>",
"      Tilazem 90 (ZA);",
"     </li>",
"     <li>",
"      Tildiem (BE, CH, CN, FR, GB, GR, IE, IT, LU, MY, NL);",
"     </li>",
"     <li>",
"      Tildiem CR (NL);",
"     </li>",
"     <li>",
"      Tildiem LA (GB);",
"     </li>",
"     <li>",
"      Tildiem Retard (GR);",
"     </li>",
"     <li>",
"      Vasocardol CD (AU);",
"     </li>",
"     <li>",
"      Zandil (PH);",
"     </li>",
"     <li>",
"      Zemtrial (PH);",
"     </li>",
"     <li>",
"      Ziruvate (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F160616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nondihydropyridine calcium channel blocker which inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F160635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: Immediate release tablet: 30-60 minutes; I.V.: 3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.V.: Bolus: 1-3 hours; Continuous infusion (after discontinuation): 0.5-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Immediate release tablet: &gt;90%; Extended release capsule: ~93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3-13 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 70% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (extensive first-pass effect); following single I.V. injection, plasma concentrations of N-monodesmethyldiltiazem and desacetyldiltiazem are typically undetectable; however, these metabolites accumulate to detectable concentrations following 24-hour constant rate infusion. N-monodesmethyldiltiazem appears to have 20% of the potency of diltiazem; desacetyldiltiazem is about 25% to 50% as potent as the parent compound.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: ~40% (undergoes extensive first-pass metabolism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Immediate release tablet: 3-4.5 hours, may be prolonged with renal impairment; Extended release tablet: 6-9 hours; Extended release capsules: 5-10 hours; I.V.: single dose: ~3.4 hours; continuous infusion: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Immediate release tablet: 2-4 hours; Extended release tablet: 11-18 hours; Extended release capsule: 10-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (2% to 4% as unchanged drug; 6% to 7% as metabolites); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      \"American Academy of Pediatrics Committee on Drugs, \"The Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, \"ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Badesch DB, Abman SH, Simonneau G, et al, \"Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines,\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2007, 131(6):1917-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/17565025/pubmed\" id=\"17565025\" target=\"_blank\">",
"        17565025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Braunwald E, Antman EM, Beasley JW, et al, \"ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction &minus; Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2002, 40(7):1366-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/12383588/pubmed\" id=\"12383588\" target=\"_blank\">",
"        12383588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, \"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ellenbogen KA, Dias VC, and Cardello FP, \"Safety and Efficacy of Intravenous Diltiazem in Atrial Fibrillation or Atrial Flutter,\"",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1995, 75(1):45-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/7801862/pubmed\" id=\"7801862\" target=\"_blank\">",
"        7801862",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, \"Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT and Pasko DA, \"Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2000, 15(3-4):302-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/11149130/pubmed\" id=\"11149130\" target=\"_blank\">",
"        11149130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, \"ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(24):e783-831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/22068434/pubmed\" id=\"22068434\" target=\"_blank\">",
"        22068434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibson RS, Boden WE, Theroux P, et al, \"Diltiazem and Reinfarction With Non-Q-Wave Myocardial Infarction,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1986, 315(7):423-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/3526151/pubmed\" id=\"3526151\" target=\"_blank\">",
"        3526151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, \"2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karth GD, Geppert A, Neunteufl T, et al, \"Amiodarone vs. Diltiazem for Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2001, 29(6):1149-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/11395591/pubmed\" id=\"11395591\" target=\"_blank\">",
"        11395591",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, \"Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maron BJ, McKenna WJ, Danielson GK, et al, \"American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2003, 42(9):1687-713.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/14607462/pubmed\" id=\"14607462\" target=\"_blank\">",
"        14607462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, \"Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips BG, Gandhi AJ, Sanoski CA, et al, \"Comparison of Intravenous Diltiazem and Verapamil for the Acute Treatment of Atrial Fibrillation and Atrial Flutter,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1997, 17(6):1238-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/9399606/pubmed\" id=\"9399606\" target=\"_blank\">",
"        9399606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts SA, Diaz C, Nolan PE, et al, \"Effectiveness and Costs of Digoxin Treatment for Atrial Fibrillation and Flutter,\"",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1993, 72(7):567-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/8362772/pubmed\" id=\"8362772\" target=\"_blank\">",
"        8362772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steele RM, Schuna AA, and Schreiber RT, \"Calcium Antagonist-Induced Gingival Hyperplasia,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 120(8):663-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/8135450/pubmed\" id=\"8135450\" target=\"_blank\">",
"        8135450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"The Effect of Diltiazem on Mortality and Reinfarction After Myocardial Infarction. The Multicenter Diltiazem Postinfarction Trial Research Group,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 319(7):385-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/2899840/pubmed\" id=\"2899840\" target=\"_blank\">",
"        2899840",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, \"2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White WB, Lacourciere Y, Gana T, et al, \"Effects of Graded-Release Diltiazem Versus Ramipril, Dosed at Bedtime, on Early Morning Blood Pressure, Heart Rate, and the Rate-Pressure Product,\"",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2004, 148(4):628-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/16/12554/abstract-text/15459593/pubmed\" id=\"15459593\" target=\"_blank\">",
"        15459593",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9365 Version 54.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12554=[""].join("\n");
var outline_f12_16_12554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160657\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160658\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160711\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160662\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160686\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160663\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160664\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160665\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160628\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6047983\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160613\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160632\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471309\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471310\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160718\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160631\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160707\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160720\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160709\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160636\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160617\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160705\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160622\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160653\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160624\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160639\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160670\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160640\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160638\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160626\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160641\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160616\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160635\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9365\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9365|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/11/6326?source=related_link\">",
"      Diltiazem: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/14/16617?source=related_link\">",
"      Diltiazem: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_16_12555="Testing in diabetic pregnancy";
var content_f12_16_12555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of testing during pregnancy in women with pregestatonal diabetes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin A1C",
"       </td>",
"       <td>",
"        Every 4 to 6 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood glucose",
"       </td>",
"       <td>",
"        Home measurements 4 to 8 times daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine ketones",
"       </td>",
"       <td>",
"        During period of illness; when any blood glucose value is &gt;200 mg/dL (11.1 mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine protein",
"       </td>",
"       <td>",
"        Diptstick at office visits, quantitate 24 hour excretion each trimester in women with nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum creatinine",
"       </td>",
"       <td>",
"        Each trimester in women with nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid function tests",
"       </td>",
"       <td>",
"        Baseline measurements of serum free T4 and TSH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eye examination",
"       </td>",
"       <td>",
"        Baseline and then as necessary per retinal specialist",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12555=[""].join("\n");
var outline_f12_16_12555=null;
var title_f12_16_12556="Indications for OB ultrasound";
var content_f12_16_12556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for ultrasound examination during pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Determine the location of pregnancy (intrauterine or extrauterine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Estimate gestational age and date of delivery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Confirm fetal cardiac activity or fetal death",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate vaginal bleeding or pelvic pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate a significant uterine size and dates discrepancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diagnose suspected multiple gestation and determine chorionicity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate fetus for anomalies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate fetal weight and growth over time",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       As an adjunct to diagnostic or therapeutic procedures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate suspected gestational trophoblastic disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate cervix for risk of preterm loss or birth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate a pelvic mass",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Follow-up of a previously detected abnormality",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       As part of fetal aneuploidy screening",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate a suspected uterine abnormality",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       As part of the evaluation of abnormal maternal analytes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Biophysical fetal evaluation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate suspected abnormalities of amniotic fluid volume (oligohydramnios, polyhydramnios)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate suspected abruptio placentae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaluate and follow-up suspected placenta previa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Determine fetal presentation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       As part of an evaluation for premature rupture of membranes or premature labor",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    A sonographic study should only be performed for a valid medical indication. Nonmedical use of obstetric ultrasonography has been discouraged by major socities, including the American College of Obstetricians and Gynecologists (ACOG), the American Institute of Ultrasound in Medicine (AIUM), and the International Society of Ultrasound in Obstetrics and Gynecology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American College of Obstetricians and Gynecologists Practice Bulletin No. 98. Ultrasonography in pregnancy. Obstet Gynecol 2008; 112:951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12556=[""].join("\n");
var outline_f12_16_12556=null;
var title_f12_16_12557="Laboratory parameters HAT";
var content_f12_16_12557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory parameters of HAT",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"30%\">",
"     </colgroup>",
"     <colgroup span=\"4\" width=\"17%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Travelers",
"       </td>",
"       <td class=\"subtitle1\">",
"        Immigrants",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Fisher test p-value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        T.b. rhodesiense",
"       </td>",
"       <td class=\"subtitle2\">",
"        T.b. gambiense",
"       </td>",
"       <td class=\"subtitle2\">",
"        T.b. gambiense",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Elevated inflammatory parameter",
"        </strong>",
"        *",
"       </td>",
"       <td class=\"centered\">",
"        8/8 = 100 percent",
"       </td>",
"       <td class=\"centered\">",
"        8/9 = 88.9 percent",
"       </td>",
"       <td class=\"centered\">",
"        6/6 = 100 percent",
"       </td>",
"       <td class=\"centered\">",
"        1.000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         WBC &lt;3.5x10",
"         <sup>",
"          3",
"         </sup>",
"         /mm",
"         <sup>",
"          3",
"         </sup>",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        15/43 = 34.9 percent",
"       </td>",
"       <td class=\"centered\">",
"        3/7 = 42.9 percent",
"       </td>",
"       <td class=\"centered\">",
"        1/12 = 8.3 percent",
"       </td>",
"       <td class=\"centered\">",
"        0.164",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         WBC &gt;9.06x10",
"         <sup>",
"          3",
"         </sup>",
"         /mm",
"         <sup>",
"          3",
"         </sup>",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        5/43 = 11.6 percent",
"       </td>",
"       <td class=\"centered\">",
"        2/7 = 28.6 percent",
"       </td>",
"       <td class=\"centered\">",
"        3/12 = 25 percent",
"       </td>",
"       <td class=\"centered\">",
"        0.289",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Hb &lt;12 g/dL (female)&nbsp;and &lt;13.3 g/dL (male)",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        18/34 = 52.9 percent",
"       </td>",
"       <td class=\"centered\">",
"        8/9 = 88.9 percent",
"       </td>",
"       <td class=\"centered\">",
"        11/11 = 100 percent",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         0.003",
"        </p>",
"        0.0489",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Platelets &lt;165 000/mm",
"         <sup>",
"          3",
"         </sup>",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        37/42 = 88.1 percent",
"       </td>",
"       <td class=\"centered\">",
"        3/5 = 60 percent",
"       </td>",
"       <td class=\"centered\">",
"        5/8 = 62.5 percent",
"       </td>",
"       <td class=\"centered\">",
"        0.082",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Elevated liver enzymes",
"        </strong>",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        31/35 s = 80.7 percent",
"       </td>",
"       <td class=\"centered\">",
"        1/3 = 33.3 percent",
"       </td>",
"       <td class=\"centered\">",
"        0/3 = 0 percent",
"       </td>",
"       <td class=\"centered\">",
"        0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total bilirubi &gt;1.3 mg/dL",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        17/22 = 77.3 percent",
"       </td>",
"       <td class=\"centered\">",
"        No data",
"       </td>",
"       <td class=\"centered\">",
"        0/2 = 0 percent",
"       </td>",
"       <td class=\"centered\">",
"        0.076",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Creatinin &gt;0.9 mg/dL (female) and &gt;1.2 (male)",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        24/29 = 82.8 percent",
"       </td>",
"       <td class=\"centered\">",
"        0/3 = 0 percent",
"       </td>",
"       <td class=\"centered\">",
"        0/4 = 0 percent",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         0.0016",
"        </p>",
"        0.001",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal reference of value out of Harrison's Online (file://www.accessmedicine.com/popup.aspx?alD=2904606).",
"    <div class=\"footnotes\">",
"     * At least one of the following parameters was elevated: C-reactive protein (CRP)&gt;3.0 mg/L; erythrocyte sedimentation rate female &gt;20 mm/h, male &gt;15 mm/h.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      At least one of the following parameters was elevated: Alanin aminotransferase (SGOT, ALAT) &gt;7 to 41 U/I; Aspartate aminotransferase (SGPT, ASAT) &gt;12 to 38 U/I; Alkaline Phosphatase (ALP) &gt;60 to 170 U7I).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - Do they really sleep? PLoS Negl Trop Dis 2011; 5:e1358. Copyright &copy; 2011 Public Library of Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12557=[""].join("\n");
var outline_f12_16_12557=null;
var title_f12_16_12558="Serum testosterone level across gestation";
var content_f12_16_12558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Total and free testosterone during pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 499px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in serum total (left) and free (right) testosterone concentrations during normal pregnancy. The normal range is bounded by the dashed lines. There is a progressive rise in total testosterone, due primarily to increases in serum sex hormone-binding globulin. The free testosterone concentration is stable until the third trimester when it increases about two-fold. To convert serum total and free testosterone values to nmol/L, multiply by 0.035.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bammann, BL, Coulam, CB, Jiang, NS, Am J Obstet Gynecol 1980; 137:293.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12558=[""].join("\n");
var outline_f12_16_12558=null;
var title_f12_16_12559="Pericentric inversion";
var content_f12_16_12559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pericentric inversion of chromosome 7",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a pericentric inversion, the inverted chromosome segment involves part of both chromosome arms and spans the centromere. This patient (GTG stained chromosome on the right) has a pericentric inversion of chromosome 7. The boxed area corresponds to the area between the two red arrows in the normal chromosome 7 (center) and to the indicated bands on the representation of chromosome 17 (left). The black bar to the left of both GTG banded chromosomes shows the location of the centromere. This pericentric inversion changed the position of the centromere.",
"    <div class=\"footnotes\">",
"     GTG: G-banding with trypsin and Giemsa",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_16_12559=[""].join("\n");
var outline_f12_16_12559=null;
